Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References FTP Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:panobinostat
go back to main search page
Accession:CHEBI:85990 term browser browse the term
Definition:A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
Synonyms:exact_synonym: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
 related_synonym: Formula=C21H23N3O2;   InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+;   InChIKey=FPOHNWQLNRZRFC-ZHACJKMWSA-N;   LBH 589;   LBH589;   SMILES=Cc1[nH]c2ccccc2c1CCNCc1ccc(\\C=C\\C(=O)NO)cc1
 alt_id: MESH:C496932
 xref: CAS:404950-80-7;   Drug_Central:4682;   KEGG:D10319
 xref_mesh: MESH:C496932
 xref: PMID:25305451;   PMID:25377157;   PMID:25410127;   PMID:25458954;   PMID:25572329;   PMID:25608569;   PMID:25612941;   PMID:25628765;   PMID:25710456;   PMID:25802326;   PMID:25837990;   PMID:25870990;   PMID:25904215;   PMID:25939707;   PMID:25944617;   PMID:26000292;   PMID:26030093;   PMID:26051506;   Reaxys:12257756;   Wikipedia:Panobinostat
 cyclic_relationship: is_conjugate_base_of CHEBI:85992

show annotations for term's descendants           Sort by:
 
panobinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2ml1 alpha-2-macroglobulin-like 1 decreases expression ISO Panobinostat results in decreased expression of OVOS2 mRNA CTD PMID:26272509 NCBI chr 4:161,863,609...161,907,897
Ensembl chr 4:161,866,078...161,907,767 		JBrowse link
G Abat 4-aminobutyrate aminotransferase increases expression
multiple interactions		 ISO panobinostat results in increased expression of ABAT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:7,093,406...7,200,439
Ensembl chr10:7,093,405...7,200,499 		JBrowse link
G Abca5 ATP binding cassette subfamily A member 5 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA
panobinostat results in decreased expression of ABCA5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA CTD PMID:27188386 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621 		JBrowse link
G Abhd14a abhydrolase domain containing 14A decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:115,141,575...115,151,222
Ensembl chr 8:115,141,539...115,149,527 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA CTD PMID:21791302 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388 		JBrowse link
G Acad11 acyl-CoA dehydrogenase family, member 11 increases expression ISO panobinostat results in increased expression of ACAD11 mRNA CTD PMID:26272509 NCBI chr 8:112,594,758...112,676,275
Ensembl chr 8:112,594,691...112,676,280 		JBrowse link
G Ackr3 atypical chemokine receptor 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ACKR3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445 		JBrowse link
G Acp3 acid phosphatase 3 increases expression
multiple interactions		 ISO Panobinostat results in increased expression of ACP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:112,838,574...112,884,062
Ensembl chr 8:112,834,707...112,884,077 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA
panobinostat results in increased expression of ACSL1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246 		JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 increases expression ISO panobinostat results in increased expression of ACSM3 mRNA CTD PMID:26272509 NCBI chr 1:189,514,504...189,541,233
Ensembl chr 1:189,514,553...189,541,224 		JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression ISO Panobinostat results in decreased expression of ACTA2 mRNA CTD PMID:30481203 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394 		JBrowse link
G Ada adenosine deaminase multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA
panobinostat results in decreased expression of ADA mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947 		JBrowse link
G Adam12 ADAM metallopeptidase domain 12 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ADAM12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:205,951,840...206,286,294
Ensembl chr 1:205,956,342...206,282,575 		JBrowse link
G Adam22 ADAM metallopeptidase domain 22 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA
panobinostat results in decreased expression of ADAM22 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:22,864,485...23,002,969
Ensembl chr 4:22,859,622...22,996,645 		JBrowse link
G Adam28 ADAM metallopeptidase domain 28 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA
panobinostat results in increased expression of ADAM28 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:50,356,745...50,425,911
Ensembl chr15:50,358,192...50,425,900 		JBrowse link
G Adamts15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA
panobinostat results in increased expression of ADAMTS15 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:31,977,001...32,000,378
Ensembl chr 8:31,977,001...32,000,378 		JBrowse link
G Adamts17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA CTD PMID:27188386 NCBI chr 1:127,802,872...128,126,764
Ensembl chr 1:127,802,978...128,124,171 		JBrowse link
G Adamts19 ADAM metallopeptidase with thrombospondin type 1 motif, 19 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA
panobinostat results in increased expression of ADAMTS19 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:53,915,807...54,099,856
Ensembl chr18:53,915,807...54,099,120 		JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ADCYAP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716 		JBrowse link
G Adcyap1r1 ADCYAP receptor type I multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA
panobinostat results in increased expression of ADCYAP1R1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA
panobinostat results in decreased expression of ADGRG1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674 		JBrowse link
G Adgrg6 adhesion G protein-coupled receptor G6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA CTD PMID:27188386 NCBI chr 1:8,593,342...8,751,540
Ensembl chr 1:8,593,075...8,751,198 		JBrowse link
G Adgrl3 adhesion G protein-coupled receptor L3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ADGRL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:28,362,176...29,226,085
Ensembl chr14:28,393,394...28,967,980 		JBrowse link
G Adgrv1 adhesion G protein-coupled receptor V1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA
panobinostat results in decreased expression of ADGRV1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:8,926,843...9,504,455
Ensembl chr 2:8,926,850...9,504,134 		JBrowse link
G Adra2a adrenoceptor alpha 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA CTD PMID:27188386 NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081 		JBrowse link
G Afap1l1 actin filament associated protein 1-like 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of AFAP1L1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:57,052,659...57,114,589
Ensembl chr18:57,053,947...57,114,545 		JBrowse link
G Ahnak AHNAK nucleoprotein increases expression
multiple interactions		 ISO panobinostat results in increased expression of AHNAK mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:225,184,883...225,429,638
Ensembl chr 1:225,184,939...225,215,015 		JBrowse link
G Ajap1 adherens junctions associated protein 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA
panobinostat results in increased expression of AJAP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:170,615,885...170,679,315
Ensembl chr 5:170,615,886...170,679,315 		JBrowse link
G Akap12 A-kinase anchoring protein 12 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA
panobinostat results in decreased expression of AKAP12 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:40,816,130...40,906,582
Ensembl chr 1:40,816,107...40,906,581 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein CTD PMID:18445700 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258 		JBrowse link
G Alcam activated leukocyte cell adhesion molecule increases expression
multiple interactions		 ISO panobinostat results in increased expression of ALCAM mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:50,780,735...50,985,083
Ensembl chr11:50,781,127...50,985,083 		JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ALDH1A2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489 		JBrowse link
G Aldh1a3 aldehyde dehydrogenase 1 family, member A3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882 		JBrowse link
G Aldh1l2 aldehyde dehydrogenase 1 family, member L2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:26,375,866...26,425,838
Ensembl chr 7:26,375,866...26,425,108 		JBrowse link
G Alkal2 ALK and LTK ligand 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA
panobinostat results in increased expression of ALKAL2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:49,824,725...49,834,921
Ensembl chr 6:49,825,469...49,834,912 		JBrowse link
G Alx1 ALX homeobox 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ALX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:44,751,865...44,771,458
Ensembl chr 7:44,751,873...44,771,458 		JBrowse link
G Amer2 APC membrane recruitment protein 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of AMER2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:40,663,183...40,667,705
Ensembl chr15:40,665,041...40,667,173 		JBrowse link
G Amigo2 adhesion molecule with Ig like domain 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA
panobinostat results in increased expression of AMIGO2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:138,704,124...138,707,221
Ensembl chr 7:138,704,126...138,707,221 		JBrowse link
G Ang angiogenin multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA CTD PMID:27188386 NCBI chr15:28,022,926...28,028,636 JBrowse link
G Angpt1 angiopoietin 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA
panobinostat results in increased expression of ANGPT1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206 		JBrowse link
G Angpt2 angiopoietin 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA
panobinostat results in increased expression of ANGPT2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195 		JBrowse link
G Ankh ANKH inorganic pyrophosphate transport regulator multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA
panobinostat results in increased expression of ANKH mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:80,131,563...80,256,948
Ensembl chr 2:80,131,563...80,256,954 		JBrowse link
G Ankrd1 ankyrin repeat domain 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA
panobinostat results in increased expression of ANKRD1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:254,726,985...254,745,673
Ensembl chr 1:254,726,969...254,735,548 		JBrowse link
G Ankrd22 ankyrin repeat domain 22 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA CTD PMID:27188386 NCBI chr 1:252,430,750...252,461,346
Ensembl chr 1:252,429,677...252,461,461 		JBrowse link
G Anks1b ankyrin repeat and sterile alpha motif domain containing 1B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA CTD PMID:27188386 NCBI chr 7:30,507,135...31,684,604
Ensembl chr 7:30,699,476...31,681,182 		JBrowse link
G Ano3 anoctamin 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA CTD PMID:27188386 NCBI chr 3:101,843,516...102,203,368
Ensembl chr 3:101,840,630...102,151,489 		JBrowse link
G Anos1 anosmin 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA
panobinostat results in decreased expression of KAL1 mRNA		 CTD PMID:26272509, PMID:27188386 Ensembl chr10:70,999,780...71,000,627 JBrowse link
G Anxa1 annexin A1 increases expression ISO panobinostat results in increased expression of ANXA1 mRNA CTD PMID:26272509 NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012 		JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ANXA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594 		JBrowse link
G Anxa3 annexin A3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA
panobinostat results in increased expression of ANXA3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437 		JBrowse link
G Anxa9 annexin A9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA CTD PMID:27188386 NCBI chr 2:196,470,318...196,481,568
Ensembl chr 2:196,470,858...196,479,770 		JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of AOX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870 		JBrowse link
G Ap1m2 adaptor related protein complex 1 subunit mu 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA
panobinostat results in increased expression of AP1M2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:22,318,941...22,336,827
Ensembl chr 8:22,319,331...22,336,794 		JBrowse link
G Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ARAP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:48,726,033...48,922,809
Ensembl chr14:48,726,045...48,922,983 		JBrowse link
G Arfgef3 ARFGEF family member 3 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA
panobinostat results in decreased expression of ARFGEF3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:13,837,861...13,918,277
Ensembl chr 1:13,838,707...13,915,594 		JBrowse link
G Arhgap15 Rho GTPase activating protein 15 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA
panobinostat results in decreased expression of ARHGAP15 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:28,626,987...29,236,225
Ensembl chr 3:28,627,084...29,236,219 		JBrowse link
G Arhgap18 Rho GTPase activating protein 18 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA
panobinostat results in increased expression of ARHGAP18 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:19,227,115...19,463,139
Ensembl chr 1:19,227,121...19,376,301 		JBrowse link
G Arhgap24 Rho GTPase activating protein 24 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA CTD PMID:27188386 NCBI chr14:8,383,211...8,600,526
Ensembl chr14:8,383,214...8,600,512 		JBrowse link
G Arhgap31 Rho GTPase activating protein 31 multiple interactions
affects expression		 ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARHGAP31 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARHGAP31 mRNA] CTD PMID:26733615 NCBI chr11:64,600,968...64,714,114
Ensembl chr11:64,601,029...64,714,252 		JBrowse link
G Arhgap5 Rho GTPase activating protein 5 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ARHGAP5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:73,345,129...73,408,304
Ensembl chr 6:73,345,392...73,405,880 		JBrowse link
G Arhgap6 Rho GTPase activating protein 6 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ARHGAP6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:26,314,561...26,845,242
Ensembl chr  X:26,315,878...26,376,467 		JBrowse link
G Arid2 AT-rich interaction domain 2 affects expression
multiple interactions		 ISO panobinostat affects the expression of ARID2 mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARID2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARID2 mRNA]		 CTD PMID:26733615 NCBI chr 7:137,680,564...137,798,329
Ensembl chr 7:137,680,530...137,795,655 		JBrowse link
G Arid5b AT-rich interaction domain 5B multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA
panobinostat results in increased expression of ARID5B mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:21,713,900...21,881,193
Ensembl chr20:21,564,975...21,880,715 		JBrowse link
G Armh4 armadillo-like helical domain containing 4 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA
panobinostat results in decreased expression of ARMH4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:26,586,359...26,687,412
Ensembl chr15:26,587,179...26,678,420 		JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ARNT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171 		JBrowse link
G Arntl2 aryl hydrocarbon receptor nuclear translocator-like 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of ARNTL2 mRNA CTD PMID:21791302 NCBI chr 4:181,103,774...181,158,415
Ensembl chr 4:181,103,774...181,214,994 		JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ARRB1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139 		JBrowse link
G Arx aristaless related homeobox decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ARX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:62,363,757...62,376,139
Ensembl chr  X:62,363,757...62,376,143 		JBrowse link
G As3mt arsenite methyltransferase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of AS3MT mRNA CTD PMID:21791302 NCBI chr 1:266,482,787...266,514,570
Ensembl chr 1:266,482,858...266,514,569 		JBrowse link
G Asb9 ankyrin repeat and SOCS box-containing 9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA CTD PMID:27188386 NCBI chr  X:31,700,637...31,745,790
Ensembl chr  X:31,700,633...31,780,425 		JBrowse link
G Ascl1 achaete-scute family bHLH transcription factor 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA CTD PMID:27188386 NCBI chr 7:28,038,662...28,040,504
Ensembl chr 7:28,038,662...28,040,510 		JBrowse link
G Asic1 acid sensing ion channel subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA CTD PMID:27188386 NCBI chr 7:141,324,714...141,354,937
Ensembl chr 7:141,326,321...141,354,937 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions		 ISO panobinostat results in increased expression of ASNS mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163 		JBrowse link
G Ass1 argininosuccinate synthase 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ASS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:10,327,411...10,375,847
Ensembl chr 3:10,327,414...10,375,826 		JBrowse link
G Astn1 astrotactin 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:76,054,965...76,370,674
Ensembl chr13:76,055,410...76,370,674 		JBrowse link
G Astn2 astrotactin 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ASTN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:81,179,614...82,168,528
Ensembl chr 5:81,179,605...82,168,427 		JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO panobinostat results in increased expression of ATF3 mRNA CTD PMID:26272509 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632 		JBrowse link
G Atp13a4 ATPase 13A4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA CTD PMID:27188386 NCBI chr11:74,833,824...74,968,160
Ensembl chr11:74,834,050...74,968,336 		JBrowse link
G Atp23 ATP23 metallopeptidase and ATP synthase assembly factor homolog increases expression
multiple interactions		 ISO panobinostat results in increased expression of ATP23 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:70,183,625...70,198,655
Ensembl chr 7:70,183,625...70,198,655 		JBrowse link
G Atp2c2 ATPase secretory pathway Ca2+ transporting 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA
panobinostat results in increased expression of ATP2C2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:52,347,480...52,404,608
Ensembl chr19:52,347,580...52,404,607 		JBrowse link
G Atp6v0a2 ATPase H+ transporting V0 subunit a2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA
panobinostat results in decreased expression of ATP6V0A2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr12:37,368,321...37,398,233
Ensembl chr12:37,363,906...37,425,596 		JBrowse link
G Atp6v0a4 ATPase H+ transporting V0 subunit a4 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA
panobinostat results in increased expression of ATP6V0A4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:65,736,585...65,821,916
Ensembl chr 4:65,736,585...65,818,521 		JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA
panobinostat results in increased expression of ATP6V0D2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:33,843,591...33,892,446
Ensembl chr 5:33,843,519...33,892,462 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA
panobinostat results in increased expression of ATP8B1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354 		JBrowse link
G Atp8b3 ATPase phospholipid transporting 8B3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA
panobinostat results in increased expression of ATP8B3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:12,043,764...12,063,668
Ensembl chr 7:12,043,794...12,063,650 		JBrowse link
G Atp9a ATPase phospholipid transporting 9A (putative) multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA
panobinostat results in decreased expression of ATP9A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:165,405,588...165,511,104
Ensembl chr 3:165,412,803...165,477,771 		JBrowse link
G Axin2 axin 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA
panobinostat results in increased expression of AXIN2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642 		JBrowse link
G B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA
panobinostat results in increased expression of B3GNT7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:93,326,283...93,330,234
Ensembl chr 9:93,326,283...93,330,233 		JBrowse link
G Bace2 beta-secretase 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of BACE2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:37,798,397...37,880,624
Ensembl chr11:37,798,370...37,880,821 		JBrowse link
G Bag2 BAG cochaperone 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
panobinostat results in increased expression of BAG2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:38,456,487...38,467,120
Ensembl chr 9:38,456,468...38,467,118 		JBrowse link
G Bag5 BAG cochaperone 5 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BAG5 mRNA CTD PMID:21791302 NCBI chr 6:136,180,640...136,185,651
Ensembl chr 6:136,182,006...136,185,651 		JBrowse link
G Bambi BMP and activin membrane-bound inhibitor increases expression
multiple interactions		 ISO panobinostat results in increased expression of BAMBI mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992 		JBrowse link
G Batf3 basic leucine zipper ATF-like transcription factor 3 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BATF3 mRNA CTD PMID:21791302 NCBI chr13:109,713,376...109,726,438
Ensembl chr13:109,713,489...109,724,863 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat] CTD PMID:18445700 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207 		JBrowse link
G Baz1a bromodomain adjacent to zinc finger domain, 1A multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA
panobinostat results in increased expression of BAZ1A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:75,793,223...75,873,854
Ensembl chr 6:75,793,960...75,874,235 		JBrowse link
G Bcl11a BAF chromatin remodeling complex subunit BCL11A increases expression
multiple interactions		 ISO panobinostat results in increased expression of BCL11A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:108,826,717...108,921,197
Ensembl chr14:108,826,831...108,921,669 		JBrowse link
G Bcl2 BCL2, apoptosis regulator affects expression
multiple interactions
decreases expression		 ISO panobinostat affects the expression of BCL2 mRNA
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of BCL2 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [Panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of BCL2 protein; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BCL2 mRNA]
panobinostat results in decreased expression of BCL2 mRNA; panobinostat results in decreased expression of BCL2 protein		 CTD PMID:24435446, PMID:26272509, PMID:26733615, PMID:27188386 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374 		JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
decreases expression		 ISO (+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein]
panobinostat results in increased expression of BCL2L11 protein
panobinostat results in decreased expression of BCL2L11 mRNA		 CTD PMID:24435446, PMID:26272509, PMID:27188386 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192 		JBrowse link
G Begain brain-enriched guanylate kinase-associated multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA
panobinostat results in decreased expression of BEGAIN mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:132,936,964...132,972,569
Ensembl chr 6:132,936,970...132,972,511 		JBrowse link
G Best4 bestrophin 4 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA
panobinostat results in decreased expression of BEST4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:136,013,978...136,017,742
Ensembl chr 5:136,014,017...136,017,677 		JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression
multiple interactions		 ISO panobinostat results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319 		JBrowse link
G Bhlhe41 basic helix-loop-helix family, member e41 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BHLHE41 mRNA CTD PMID:21791302 NCBI chr 4:180,230,742...180,235,138
Ensembl chr 4:180,232,382...180,234,804 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO Panobinostat results in decreased expression of BIRC5 mRNA CTD PMID:30481203 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413 		JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA
panobinostat results in increased expression of BMP2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318 		JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA
panobinostat results in increased expression of BMP4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740 		JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
panobinostat results in increased expression of BMP5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:82,669,466...82,950,273
Ensembl chr 8:82,878,941...82,950,273 		JBrowse link
G Bmp7 bone morphogenetic protein 7 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA
panobinostat results in increased expression of BMP7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399 		JBrowse link
G Bmper BMP-binding endothelial regulator multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA
panobinostat results in increased expression of BMPER mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:24,369,916...24,615,484
Ensembl chr 8:24,369,916...24,615,479 		JBrowse link
G Bmpr1b bone morphogenetic protein receptor type 1B multiple interactions
affects expression		 ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of BMPR1B mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BMPR1B mRNA] CTD PMID:26733615 NCBI chr 2:247,392,195...247,662,026
Ensembl chr 2:247,403,920...247,446,882 		JBrowse link
G Bnc2 basonuclin 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of BNC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:102,407,508...102,807,389
Ensembl chr 5:102,415,847...102,786,331 		JBrowse link
G Bnipl BCL2 interacting protein like multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA
panobinostat results in increased expression of BNIPL mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:196,415,736...196,425,727
Ensembl chr 2:196,415,738...196,425,727 		JBrowse link
G Boc BOC cell adhesion associated, oncogene regulated multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA
panobinostat results in increased expression of BOC mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:61,084,216...61,159,220
Ensembl chr11:61,083,757...61,158,838 		JBrowse link
G Bri3bp Bri3 binding protein increases expression ISO panobinostat results in increased expression of BRI3BP mRNA CTD PMID:26272509 NCBI chr12:36,576,018...36,587,839
Ensembl chr12:36,576,020...36,587,839 		JBrowse link
G Brinp1 BMP/retinoic acid inducible neural specific 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of BRINP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:84,919,416...85,123,828
Ensembl chr 5:84,919,367...85,123,829 		JBrowse link
G Brip1 BRCA1 interacting protein C-terminal helicase 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA CTD PMID:27188386 NCBI chr10:73,507,009...73,632,742
Ensembl chr10:73,507,100...73,629,581 		JBrowse link
G Bspry B-box and SPRY domain containing increases expression
multiple interactions		 ISO panobinostat results in increased expression of BSPRY mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:78,334,284...78,356,462
Ensembl chr 5:78,334,284...78,356,460 		JBrowse link
G C1galt1 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA
panobinostat results in increased expression of C1GALT1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:33,890,353...33,943,219
Ensembl chr 4:33,890,349...33,943,211 		JBrowse link
G C1qtnf4 C1q and TNF related 4 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA
panobinostat results in decreased expression of C1QTNF4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:79,713,580...79,718,018
Ensembl chr 3:79,713,567...79,718,025 		JBrowse link
G C2cd2 C2 calcium-dependent domain containing 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA
panobinostat results in decreased expression of C2CD2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:38,354,746...38,420,133
Ensembl chr11:38,357,424...38,420,119 		JBrowse link
G C3 complement C3 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of C3 mRNA CTD PMID:21791302 NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167 		JBrowse link
G Ca12 carbonic anhydrase 12 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CA12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240 		JBrowse link
G Ca13 carbonic anhydrase 13 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA CTD PMID:27188386 NCBI chr 2:88,282,961...88,314,254
Ensembl chr 2:88,282,961...88,314,254 		JBrowse link
G Ca4 carbonic anhydrase 4 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067 		JBrowse link
G Ca8 carbonic anhydrase 8 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CA8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:21,249,018...21,345,810
Ensembl chr 5:21,249,020...21,345,810 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CACNA2D1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:15,706,974...16,130,848
Ensembl chr 4:15,710,417...16,130,848 		JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CACNB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682 		JBrowse link
G Cadm4 cell adhesion molecule 4 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CADM4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:81,365,200...81,369,841
Ensembl chr 1:81,365,138...81,370,109 		JBrowse link
G Calb2 calbindin 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CALB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:41,482,743...41,509,617
Ensembl chr19:41,482,728...41,509,658 		JBrowse link
G Calca calcitonin-related polypeptide alpha increases expression
multiple interactions		 ISO panobinostat results in increased expression of CALCA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911 		JBrowse link
G Capn6 calpain 6 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CAPN6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:115,049,113...115,073,824
Ensembl chr  X:115,049,154...115,073,890 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [resveratrol co-treated with panobinostat] results in increased cleavage of CASP3 protein CTD PMID:22923501 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204 		JBrowse link
G Casp8 caspase 8 multiple interactions
increases expression		 ISO [Cisplatin co-treated with Panobinostat] affects the expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [Panobinostat co-treated with Vorinostat] results in increased cleavage of CASP8 protein; [Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein; CASP8 protein affects the susceptibility to [Resveratrol co-treated with Panobinostat]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein]
panobinostat results in increased expression of CASP8 mRNA		 CTD PMID:21791302, PMID:22923501, PMID:26272509, PMID:27188386 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO [resveratrol co-treated with panobinostat] results in increased cleavage of CASP9 protein CTD PMID:22923501 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778 		JBrowse link
G Cblc Cbl proto-oncogene C increases expression
multiple interactions		 ISO panobinostat results in increased expression of CBLC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:80,699,321...80,716,146
Ensembl chr 1:80,699,323...80,716,146 		JBrowse link
G Cc2d2a coiled-coil and C2 domain containing 2A multiple interactions
affects expression		 ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CC2D2A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CC2D2A mRNA] CTD PMID:26733615 NCBI chr14:71,895,128...71,979,452
Ensembl chr14:71,895,246...71,973,419 		JBrowse link
G Ccdc136 coiled-coil domain containing 136 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:56,674,737...56,704,501
Ensembl chr 4:56,674,832...56,704,549 		JBrowse link
G Ccdc177 coiled-coil domain containing 177 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:104,403,617...104,410,991
Ensembl chr 6:104,406,897...104,409,005 		JBrowse link
G Ccdc69 coiled-coil domain containing 69 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA
panobinostat results in increased expression of CCDC69 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:40,392,459...40,419,567
Ensembl chr10:40,392,460...40,419,054 		JBrowse link
G Cckbr cholecystokinin B receptor decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CCKBR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:170,262,218...170,272,298
Ensembl chr 1:170,262,156...170,272,298 		JBrowse link
G Ccl26 C-C motif chemokine ligand 26 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CCL26 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr12:24,157,182...24,161,870
Ensembl chr12:24,158,766...24,161,869 		JBrowse link
G Ccn3 cellular communication network factor 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA CTD PMID:27188386 NCBI chr 7:94,375,134...94,382,154
Ensembl chr 7:94,375,020...94,383,024 		JBrowse link
G Ccng2 cyclin G2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068 		JBrowse link
G Ccnt2 cyclin T2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CCNT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:44,475,959...44,516,892
Ensembl chr13:44,475,970...44,515,739 		JBrowse link
G Cd200 Cd200 molecule multiple interactions
affects expression		 ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CD200 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CD200 mRNA] CTD PMID:26733615 NCBI chr11:60,371,617...60,398,450
Ensembl chr11:60,371,684...60,403,196 		JBrowse link
G Cd24 CD24 molecule multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA
panobinostat results in increased expression of CD24 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846 		JBrowse link
G Cd44 CD44 molecule (Indian blood group) increases expression
multiple interactions		 ISO panobinostat results in increased expression of CD44 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658 		JBrowse link
G Cd52 CD52 molecule increases expression
multiple interactions		 ISO panobinostat results in increased expression of CD52 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:152,322,910...152,324,469
Ensembl chr 5:152,322,916...152,324,469 		JBrowse link
G Cd55 CD55 molecule (Cromer blood group) multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA
panobinostat results in increased expression of CD55 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:47,125,156...47,153,557
Ensembl chr13:47,126,741...47,154,292 		JBrowse link
G Cd74 CD74 molecule multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA
panobinostat results in increased expression of CD74 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849 		JBrowse link
G Cd9 CD9 molecule multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA
panobinostat results in increased expression of CD9 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:157,977,163...158,010,091
Ensembl chr 4:157,977,162...158,010,166 		JBrowse link
G Cdc42ep3 CDC42 effector protein 3 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA
panobinostat results in decreased expression of CDC42EP3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:1,922,500...1,942,972
Ensembl chr 6:1,922,500...1,942,972 		JBrowse link
G Cdc42ep5 CDC42 effector protein 5 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA
panobinostat results in increased expression of CDC42EP5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:73,717,207...73,719,600
Ensembl chr 1:73,719,005...73,719,529 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA
panobinostat results in increased expression of CDH1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395 		JBrowse link
G Cdh10 cadherin 10 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA
panobinostat results in increased expression of CDH10 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:69,415,174...69,636,849
Ensembl chr 2:69,415,057...69,637,524 		JBrowse link
G Cdh18 cadherin 18 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CDH18 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:73,651,408...74,693,342
Ensembl chr 2:74,360,622...74,693,341 		JBrowse link
G Cdh2 cadherin 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA
panobinostat results in decreased expression of CDH2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684 		JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CDH3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:38,668,957...38,719,801
Ensembl chr19:38,669,230...38,719,677 		JBrowse link
G Cdh8 cadherin 8 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CDH8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:6,031,654...6,431,502
Ensembl chr19:6,046,665...6,426,216 		JBrowse link
G Cdk19 cyclin-dependent kinase 19 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA CTD PMID:27188386 NCBI chr20:45,458,499...45,598,799
Ensembl chr20:45,458,558...45,598,798 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
increases expression		 ISO [(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of CDK6 protein; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA
panobinostat results in increased expression of CDK6 mRNA		 CTD PMID:24435446, PMID:26272509, PMID:27188386 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO panobinostat results in increased expression of CDKN1A protein CTD PMID:18445700 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression ISO panobinostat results in increased expression of CDKN1B protein CTD PMID:18445700 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964 		JBrowse link
G Cdon cell adhesion associated, oncogene regulated increases expression
multiple interactions		 ISO panobinostat results in increased expression of CDON mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:36,625,757...36,712,091
Ensembl chr 8:36,625,733...36,710,949 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA
panobinostat results in increased expression of CEBPB mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression
multiple interactions		 ISO panobinostat results in increased expression of CEBPD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146 		JBrowse link
G Celf5 CUGBP, Elav-like family member 5 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CELF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:11,095,449...11,119,941
Ensembl chr 7:11,095,468...11,119,941 		JBrowse link
G Cep85l centrosomal protein 85-like multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA
panobinostat results in increased expression of CEP85L mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:34,574,043...34,743,142
Ensembl chr20:34,575,950...34,684,418 		JBrowse link
G Cfap91 cilia and flagella associated protein 91 decreases expression
multiple interactions		 ISO Panobinostat results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:64,975,499...65,019,169
Ensembl chr11:64,975,594...65,018,108 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA CTD PMID:27188386 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251 		JBrowse link
G Cgnl1 cingulin-like 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CGNL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:78,126,670...78,278,490
Ensembl chr 8:78,126,675...78,233,430 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO panobinostat results in increased expression of CHAC1 mRNA CTD PMID:26272509 NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425 		JBrowse link
G Chga chromogranin A multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA
panobinostat results in increased expression of CHGA mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568 		JBrowse link
G Chodl chondrolectin multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
panobinostat results in increased expression of CHODL mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:17,537,980...17,560,305
Ensembl chr11:17,538,063...17,560,296 		JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA
panobinostat results in increased expression of CHRM3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:63,990,599...64,463,222
Ensembl chr17:63,990,599...63,994,169 		JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA CTD PMID:27188386 NCBI chr 8:59,594,007...59,607,122
Ensembl chr 8:59,592,403...59,607,275 		JBrowse link
G Chst15 carbohydrate sulfotransferase 15 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CHST15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:204,243,396...204,328,960
Ensembl chr 1:204,245,645...204,322,544 		JBrowse link
G Chst4 carbohydrate sulfotransferase 4 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA
panobinostat results in increased expression of CHST4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:41,630,060...41,642,373
Ensembl chr19:41,631,715...41,640,367 		JBrowse link
G Chsy1 chondroitin sulfate synthase 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA
panobinostat results in increased expression of CHSY1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:127,010,587...127,071,570
Ensembl chr 1:127,010,588...127,071,570 		JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA
panobinostat results in increased expression of CITED2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786 		JBrowse link
G Cldn1 claudin 1 increases expression ISO panobinostat results in increased expression of CLDN1 mRNA CTD PMID:26272509 NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416 		JBrowse link
G Cldn23 claudin 23 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CLDN23 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:59,988,603...59,990,327
Ensembl chr16:59,988,603...59,990,326 		JBrowse link
G Cldn4 claudin 4 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CLDN4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr12:24,761,210...24,763,008
Ensembl chr12:24,761,210...24,763,005 		JBrowse link
G Cldn6 claudin 6 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA
panobinostat results in increased expression of CLDN6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:12,999,256...13,002,860
Ensembl chr10:13,000,090...13,002,862 		JBrowse link
G Cldn7 claudin 7 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CLDN7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:56,576,326...56,578,632
Ensembl chr10:56,576,428...56,578,626 		JBrowse link
G Clgn calmegin decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CLGN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:24,545,257...24,578,527
Ensembl chr19:24,545,318...24,576,798 		JBrowse link
G Clic6 chloride intracellular channel 6 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CLIC6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:32,655,653...32,698,004
Ensembl chr11:32,655,616...32,699,382 		JBrowse link
G Clp1 cleavage factor polyribonucleotide kinase subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA CTD PMID:27188386 NCBI chr 3:72,125,269...72,137,122
Ensembl chr 3:72,125,273...72,128,973 		JBrowse link
G Clstn2 calsyntenin 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA
panobinostat results in increased expression of CLSTN2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:105,322,577...106,036,821
Ensembl chr 8:105,323,837...105,462,168 		JBrowse link
G Cltrn collectrin, amino acid transport regulator multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA
panobinostat results in decreased expression of CLTRN mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:32,118,082...32,153,687
Ensembl chr  X:32,118,054...32,153,794 		JBrowse link
G Clu clusterin increases expression
multiple interactions		 ISO panobinostat results in increased expression of CLU mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857 		JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:39,711,001...39,953,860
Ensembl chr  X:39,711,201...39,951,847 		JBrowse link
G Cnmd chondromodulin increases expression
multiple interactions		 ISO panobinostat results in increased expression of CNMD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:61,923,291...61,947,840
Ensembl chr15:61,923,299...61,947,764 		JBrowse link
G Cnot4 CCR4-NOT transcription complex, subunit 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA CTD PMID:27188386 NCBI chr 4:62,561,443...62,663,225
Ensembl chr 4:62,561,444...62,663,200 		JBrowse link
G Cnrip1 cannabinoid receptor interacting protein 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA
panobinostat results in increased expression of CNRIP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:100,217,547...100,247,235
Ensembl chr14:100,217,289...100,247,235 		JBrowse link
G Cntn1 contactin 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA
panobinostat results in increased expression of CNTN1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:133,290,606...133,588,314
Ensembl chr 7:133,400,485...133,586,677 		JBrowse link
G Cntn2 contactin 2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:49,280,913...49,314,061
Ensembl chr13:49,285,310...49,313,940 		JBrowse link
G Cobl cordon-bleu WH2 repeat protein multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA
panobinostat results in increased expression of COBL mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:92,341,949...92,497,169
Ensembl chr14:92,342,957...92,577,936 		JBrowse link
G Cobll1 cordon-bleu WH2 repeat protein-like 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA
panobinostat results in increased expression of COBLL1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:51,137,104...51,298,956
Ensembl chr 3:51,137,076...51,297,852 		JBrowse link
G Col11a1 collagen type XI alpha 1 chain increases expression ISO panobinostat results in increased expression of COL11A1 mRNA CTD PMID:27188386 NCBI chr 2:216,863,423...217,056,523
Ensembl chr 2:216,863,428...217,056,523 		JBrowse link
G Col14a1 collagen type XIV alpha 1 chain multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA
panobinostat results in increased expression of COL14A1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:95,054,877...95,274,073
Ensembl chr 7:95,074,236...95,273,298 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA CTD PMID:27188386 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789 		JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
panobinostat results in increased expression of COL1A2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151 		JBrowse link
G Col23a1 collagen type XXIII alpha 1 chain increases expression
multiple interactions		 ISO panobinostat results in increased expression of COL23A1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:34,846,618...34,934,991
Ensembl chr10:34,903,343...34,933,539 		JBrowse link
G Col5a2 collagen type V alpha 2 chain increases expression ISO panobinostat results in increased expression of COL5A2 mRNA CTD PMID:26272509 NCBI chr 9:52,091,088...52,238,735
Ensembl chr 9:52,092,511...52,238,564 		JBrowse link
G Col5a3 collagen type V alpha 3 chain multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA
panobinostat results in increased expression of COL5A3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:21,786,324...21,831,751
Ensembl chr 8:21,786,324...21,831,668 		JBrowse link
G Col6a1 collagen type VI alpha 1 chain multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA
panobinostat results in increased expression of COL6A1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA
panobinostat results in increased expression of COL6A3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546 		JBrowse link
G Col9a3 collagen type IX alpha 3 chain multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA
panobinostat results in increased expression of COL9A3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:176,102,287...176,124,839
Ensembl chr 3:176,102,351...176,124,306 		JBrowse link
G Colec12 collectin sub-family member 12 increases expression
multiple interactions		 ISO panobinostat results in increased expression of COLEC12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:867,048...1,054,047
Ensembl chr18:867,048...1,052,606 		JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:69,797,558...69,902,916
Ensembl chr13:69,797,880...69,901,170 		JBrowse link
G Comtd1 catechol-O-methyltransferase domain containing 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of COMTD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:2,631,529...2,634,640
Ensembl chr15:2,631,529...2,634,640 		JBrowse link
G Coro2a coronin 2A increases expression
multiple interactions		 ISO panobinostat results in increased expression of CORO2A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:62,154,526...62,210,797
Ensembl chr 5:62,156,839...62,187,930 		JBrowse link
G Cpe carboxypeptidase E increases expression
multiple interactions		 ISO panobinostat results in increased expression of CPE mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:26,906,716...27,014,811
Ensembl chr16:26,906,716...27,014,813 		JBrowse link
G Cped1 cadherin-like and PC-esterase domain containing 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CPED1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:49,055,988...49,333,729
Ensembl chr 4:49,056,010...49,333,304 		JBrowse link
G Cpne4 copine 4 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CPNE4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:113,105,814...113,586,429
Ensembl chr 8:113,105,814...113,586,418 		JBrowse link
G Cpxm2 carboxypeptidase X (M14 family), member 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CPXM2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:204,048,785...204,161,090
Ensembl chr 1:204,048,785...204,087,001 		JBrowse link
G Cr1l complement C3b/C4b receptor 1 like increases expression
multiple interactions		 ISO panobinostat results in increased expression of CR1L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:113,824,886...113,872,097
Ensembl chr13:113,824,892...113,872,097 		JBrowse link
G Cr2 complement C3d receptor 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CR2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:113,890,274...113,927,824
Ensembl chr13:113,890,272...113,927,877 		JBrowse link
G Crabp1 cellular retinoic acid binding protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA CTD PMID:27188386 NCBI chr 8:59,344,097...59,352,135
Ensembl chr 8:59,344,083...59,352,132 		JBrowse link
G Crabp2 cellular retinoic acid binding protein 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
panobinostat results in increased expression of CRABP2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:187,322,416...187,326,794
Ensembl chr 2:184,882,969...184,883,505 		JBrowse link
G Crip1 cysteine rich protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA CTD PMID:27188386 NCBI chr 6:137,959,171...137,967,042
Ensembl chr 6:137,959,171...137,967,042 		JBrowse link
G Crispld1 cysteine-rich secretory protein LCCL domain containing 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CRISPLD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:663,750...711,033
Ensembl chr 5:670,754...711,033 		JBrowse link
G Cryba1 crystallin, beta A1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA
panobinostat results in decreased expression of CRYBA1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:65,160,777...65,167,504
Ensembl chr10:65,161,152...65,167,494 		JBrowse link
G Cryba4 crystallin, beta A4 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr12:50,407,843...50,414,434
Ensembl chr12:50,407,843...50,414,432 		JBrowse link
G Crybg1 crystallin beta-gamma domain containing 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA
panobinostat results in increased expression of CRYBG1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:48,927,942...49,123,724
Ensembl chr20:48,927,914...48,969,499 		JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA CTD PMID:27188386 NCBI chr14:1,462,292...1,467,264
Ensembl chr14:1,462,358...1,467,264 		JBrowse link
G Cspg5 chondroitin sulfate proteoglycan 5 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA
panobinostat results in decreased expression of CSPG5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:118,333,695...118,348,040
Ensembl chr 8:118,333,706...118,347,582 		JBrowse link
G Csrnp3 cysteine and serine rich nuclear protein 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA CTD PMID:27188386 NCBI chr 3:51,883,559...52,120,290
Ensembl chr 3:51,883,559...52,120,290 		JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA CTD PMID:27188386 NCBI chr 7:77,966,722...77,977,004
Ensembl chr 7:77,966,722...77,977,004 		JBrowse link
G Ctnnd2 catenin delta 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA
panobinostat results in decreased expression of CTNND2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315 		JBrowse link
G Cul3 cullin 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of CUL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:86,044,485...86,129,066
Ensembl chr 9:86,044,485...86,129,329 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA
panobinostat results in increased expression of CX3CL1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:10,644,267...10,654,861
Ensembl chr19:10,644,244...10,653,800 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA
panobinostat results in increased expression of CXCL12 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891 		JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA
panobinostat results in increased expression of CXCL14 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of CXCR4 mRNA CTD PMID:21791302 NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878 		JBrowse link
G Cxxc5 CXXC finger protein 5 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA
panobinostat results in increased expression of CXXC5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:28,626,386...28,656,916
Ensembl chr18:28,653,592...28,656,937 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA
panobinostat results in increased expression of CYP1A1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722 		JBrowse link
G Cyren cell cycle regulator of NHEJ decreases expression ISO panobinostat results in decreased expression of CYREN mRNA CTD PMID:26272509 NCBI chr 4:62,391,770...62,397,162
Ensembl chr 4:62,391,770...62,396,035 		JBrowse link
G Cyria CYFIP related Rac1 interactor A multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA
Panobinostat results in increased expression of CYRIA mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:37,555,167...37,661,196
Ensembl chr 6:37,555,182...37,665,064 		JBrowse link
G Dab1 DAB adaptor protein 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA
panobinostat results in decreased expression of DAB1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:123,154,360...124,279,170
Ensembl chr 5:123,905,166...124,280,115 		JBrowse link
G Dach2 dachshund family transcription factor 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DACH2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:84,924,570...85,484,150
Ensembl chr  X:85,338,928...85,483,719 		JBrowse link
G Dact1 dishevelled-binding antagonist of beta-catenin 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA
panobinostat results in increased expression of DACT1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:93,740,440...93,751,003
Ensembl chr 6:93,740,586...93,749,809 		JBrowse link
G Dazl deleted in azoospermia-like multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA
panobinostat results in decreased expression of DAZL mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:12,633,983...12,651,017
Ensembl chr 9:12,633,990...12,650,938 		JBrowse link
G Dcaf12l2 DDB1 and CUL4 associated factor 12-like 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA
panobinostat results in decreased expression of DCAF12L2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:130,823,651...130,825,369
Ensembl chr  X:130,823,866...130,825,305 		JBrowse link
G Dcaf4 DDB1 and CUL4 associated factor 4 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DCAF4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:107,001,763...107,027,466
Ensembl chr 6:107,001,763...107,027,456 		JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA
panobinostat results in increased expression of DCC mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:66,518,213...67,629,801
Ensembl chr18:66,523,120...67,224,566 		JBrowse link
G Dclk1 doublecortin-like kinase 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA
panobinostat results in increased expression of DCLK1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:144,646,255...144,939,389
Ensembl chr 2:144,646,308...144,936,927 		JBrowse link
G Dclk2 doublecortin-like kinase 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA
panobinostat results in decreased expression of DCLK2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:186,116,624...186,245,937
Ensembl chr 2:186,116,624...186,245,771 		JBrowse link
G Dcun1d4 defective in cullin neddylation 1 domain containing 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA CTD PMID:27188386 NCBI chr14:37,210,721...37,294,517
Ensembl chr14:37,210,721...37,294,472 		JBrowse link
G Dennd1a DENN domain containing 1A multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA
panobinostat results in decreased expression of DENND1A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:22,061,120...22,501,502
Ensembl chr 3:22,058,400...22,500,765 		JBrowse link
G Dennd1b DENN domain containing 1B multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA
panobinostat results in decreased expression of DENND1B mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:56,015,813...56,242,041
Ensembl chr13:56,015,901...56,236,677 		JBrowse link
G Dennd2a DENN domain containing 2A multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA
panobinostat results in decreased expression of DENND2A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:67,242,257...67,342,993
Ensembl chr 4:67,242,271...67,301,102 		JBrowse link
G Dennd4a DENN domain containing 4A multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA
panobinostat results in increased expression of DENND4A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:70,293,355...70,406,675
Ensembl chr 8:70,317,586...70,406,751 		JBrowse link
G Depdc1b DEP domain containing 1B decreases expression ISO panobinostat results in decreased expression of DEPDC1B mRNA CTD PMID:26272509 NCBI chr 2:39,980,796...40,069,982
Ensembl chr 2:40,000,313...40,069,975 		JBrowse link
G Depdc7 DEP domain containing 7 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DEPDC7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:94,665,714...94,687,013
Ensembl chr 3:94,665,717...94,686,989 		JBrowse link
G Deptor DEP domain containing MTOR-interacting protein increases expression
multiple interactions		 ISO panobinostat results in increased expression of DEPTOR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:94,795,161...95,000,750
Ensembl chr 7:94,795,214...94,995,809 		JBrowse link
G Dhrs3 dehydrogenase/reductase 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DHRS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:162,809,090...162,843,385
Ensembl chr 5:162,808,646...162,843,383 		JBrowse link
G Diaph2 diaphanous-related formin 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DIAPH2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:99,722,910...100,363,228 JBrowse link
G Dipk1c divergent protein kinase domain 1C decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:81,569,693...81,591,683
Ensembl chr18:81,569,910...81,590,887 		JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein increases expression
multiple interactions		 ISO panobinostat results in increased expression of DLC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:58,776,489...59,247,752
Ensembl chr16:59,077,574...59,247,754 		JBrowse link
G Dlk1 delta like non-canonical Notch ligand 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of DLK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:133,576,513...133,583,751
Ensembl chr 6:133,552,821...133,583,751 		JBrowse link
G Dlx3 distal-less homeobox 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DLX3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:82,937,971...82,943,367
Ensembl chr10:82,937,971...82,943,348 		JBrowse link
G Dlx6 distal-less homeobox 6 decreases expression ISO panobinostat results in decreased expression of DLX6 mRNA CTD PMID:26272509 NCBI chr 4:32,373,096...32,377,388
Ensembl chr 4:32,373,641...32,377,253 		JBrowse link
G Dmrta2 DMRT-like family A2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA
panobinostat results in increased expression of DMRTA2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:129,754,295...129,760,045
Ensembl chr 5:129,756,149...129,758,986 		JBrowse link
G Dner delta/notch-like EGF repeat containing multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA CTD PMID:27188386 NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220 		JBrowse link
G Dock5 dedicator of cytokinesis 5 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DOCK5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:44,449,108...44,627,774
Ensembl chr15:44,453,308...44,627,765 		JBrowse link
G Dock9 dedicator of cytokinesis 9 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DOCK9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:107,945,664...108,210,967
Ensembl chr15:107,945,664...108,210,826 		JBrowse link
G Dok5 docking protein 5 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA CTD PMID:27188386 NCBI chr 3:168,345,116...168,482,445
Ensembl chr 3:168,345,152...168,482,441 		JBrowse link
G Dppa5 developmental pluripotency associated 5 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA
panobinostat results in increased expression of DPPA5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:85,711,560...85,713,313
Ensembl chr 8:85,711,795...85,712,647
Ensembl chr 7:85,711,795...85,712,647
Ensembl chr 3:85,711,795...85,712,647 		JBrowse link
G Dsc2 desmocollin 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DSC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:11,826,705...11,858,801
Ensembl chr18:11,826,706...11,858,754 		JBrowse link
G Dst dystonin decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of DST mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:37,902,336...38,296,961
Ensembl chr 9:37,902,303...38,196,273 		JBrowse link
G Dusp10 dual specificity phosphatase 10 increases expression
multiple interactions		 ISO panobinostat results in increased expression of DUSP10 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455 		JBrowse link
G Dusp23 dual specificity phosphatase 23 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of DUSP23 mRNA CTD PMID:21791302 NCBI chr13:91,018,670...91,019,862
Ensembl chr13:91,018,510...91,020,112 		JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of DUSP4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:61,080,767...61,090,973
Ensembl chr16:61,078,175...61,091,169 		JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA
panobinostat results in increased expression of DUSP5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:274,245,184...274,258,595
Ensembl chr 1:274,245,184...274,258,595 		JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA
panobinostat results in increased expression of DYNC1I1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:30,807,755...31,121,097
Ensembl chr 4:30,807,879...31,121,090 		JBrowse link
G E2f2 E2F transcription factor 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA
panobinostat results in decreased expression of E2F2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265 		JBrowse link
G Ebf1 EBF transcription factor 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA
panobinostat results in increased expression of EBF1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:23,654,849...24,051,627
Ensembl chr10:23,661,013...24,050,209 		JBrowse link
G Ebi3 Epstein-Barr virus induced 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA CTD PMID:27188386 NCBI chr 9:11,110,874...11,114,843
Ensembl chr 9:11,110,874...11,114,843 		JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA
panobinostat results in decreased expression of ECPAS mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:75,928,510...76,040,771
Ensembl chr 5:75,931,293...76,039,760 		JBrowse link
G Edn1 endothelin 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of EDN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324 		JBrowse link
G Ednra endothelin receptor type A increases expression
multiple interactions		 ISO panobinostat results in increased expression of EDNRA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
panobinostat results in increased expression of EDNRB mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354 		JBrowse link
G Efna1 ephrin A1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA
panobinostat results in increased expression of EFNA1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222 		JBrowse link
G Efna5 ephrin A5 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA
panobinostat results in decreased expression of EFNA5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:110,054,002...110,329,878
Ensembl chr 9:110,057,155...110,225,486 		JBrowse link
G Egf epidermal growth factor decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of EGF mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfl8 EGF-like-domain, multiple 8 increases expression ISO panobinostat results in increased expression of EGFL8 mRNA CTD PMID:26272509 NCBI chr20:4,378,205...4,380,959
Ensembl chr20:4,378,206...4,380,600 		JBrowse link
G Eif3m eukaryotic translation initiation factor 3, subunit M decreases expression ISO panobinostat results in decreased expression of EIF3M mRNA CTD PMID:26272509 NCBI chr 3:94,990,086...95,007,690
Ensembl chr 3:94,990,068...95,007,712 		JBrowse link
G Eif4e3 eukaryotic translation initiation factor 4E family member 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:132,068,581...132,111,092
Ensembl chr 4:132,068,598...132,111,079 		JBrowse link
G Elf1 E74 like ETS transcription factor 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ELF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:61,772,544...61,868,442
Ensembl chr15:61,826,711...61,868,343 		JBrowse link
G Elf3 E74 like ETS transcription factor 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ELF3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:52,083,873...52,088,798
Ensembl chr13:52,083,859...52,088,780 		JBrowse link
G Elf5 E74 like ETS transcription factor 5 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ELF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:93,333,514...93,374,454
Ensembl chr 3:93,351,619...93,371,656 		JBrowse link
G Elk3 ETS transcription factor ELK3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ELK3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:34,086,213...34,149,601
Ensembl chr 7:34,086,220...34,121,694 		JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:58,486,078...58,542,884
Ensembl chr 8:58,486,078...58,542,844 		JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ELOVL2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:21,382,461...21,422,413
Ensembl chr17:21,382,455...21,422,407 		JBrowse link
G Elp4 elongator acetyltransferase complex subunit 4 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ELP4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:95,733,810...95,954,987 JBrowse link
G Emilin3 elastin microfibril interfacer 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of EMILIN3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:156,899,892...156,906,566
Ensembl chr 3:156,901,077...156,905,892 		JBrowse link
G Emp1 epithelial membrane protein 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of EMP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966 		JBrowse link
G Enox1 ecto-NOX disulfide-thiol exchanger 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA CTD PMID:27188386 NCBI chr15:59,331,134...59,884,512
Ensembl chr15:59,678,165...59,884,511 		JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA
panobinostat results in increased expression of ENPP2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001 		JBrowse link
G Eogt EGF domain specific O-linked N-acetylglucosamine transferase multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA
panobinostat results in increased expression of EOGT mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:129,477,779...129,515,435
Ensembl chr 4:129,477,807...129,515,435 		JBrowse link
G Epas1 endothelial PAS domain protein 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of EPAS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265 		JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:117,314,935...117,666,408
Ensembl chr 9:117,538,009...117,666,410 		JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 increases expression
multiple interactions		 ISO panobinostat results in increased expression of EPB41L5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:35,622,472...35,673,449
Ensembl chr13:35,580,098...35,668,968 		JBrowse link
G Epcam epithelial cell adhesion molecule multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA
panobinostat results in increased expression of EPCAM mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216 		JBrowse link
G Epha1 Eph receptor A1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA CTD PMID:27188386 NCBI chr 4:71,749,100...71,763,681
Ensembl chr 4:71,749,242...71,763,679 		JBrowse link
G Epha3 Eph receptor A3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA
panobinostat results in increased expression of EPHA3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:421,253...783,037
Ensembl chr11:421,135...782,954 		JBrowse link
G Epha4 Eph receptor A4 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA
panobinostat results in decreased expression of EPHA4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:83,111,222...83,253,486
Ensembl chr 9:83,111,222...83,253,458 		JBrowse link
G Epha7 Eph receptor A7 increases expression
multiple interactions		 ISO panobinostat results in increased expression of EPHA7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:43,602,744...43,761,198
Ensembl chr 5:43,603,043...43,757,549 		JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456 		JBrowse link
G Epn3 epsin 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA CTD PMID:27188386 NCBI chr10:82,220,762...82,231,200
Ensembl chr10:82,220,762...82,229,140 		JBrowse link
G Eps8l2 EPS8-like 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA CTD PMID:27188386 NCBI chr 1:214,327,992...214,353,466
Ensembl chr 1:214,328,071...214,353,461 		JBrowse link
G Epsti1 epithelial stromal interaction 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA
panobinostat results in increased expression of EPSTI1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:60,084,966...60,190,360
Ensembl chr15:60,084,918...60,190,363 		JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA
panobinostat results in decreased expression of ERAP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:1,410,877...1,449,734
Ensembl chr 2:1,410,934...1,449,733 		JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
panobinostat results in increased expression of ERBB3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350 		JBrowse link
G Erp27 endoplasmic reticulum protein 27 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA
panobinostat results in increased expression of ERP27 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:170,893,946...170,912,629
Ensembl chr 4:170,893,946...170,912,629 		JBrowse link
G Esrp1 epithelial splicing regulatory protein 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ESRP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:24,576,988...24,631,758
Ensembl chr 5:24,576,991...24,631,698 		JBrowse link
G Esrp2 epithelial splicing regulatory protein 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA
panobinostat results in increased expression of ESRP2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:38,113,412...38,120,578
Ensembl chr19:38,113,412...38,120,578 		JBrowse link
G Etnk1 ethanolamine kinase 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ETNK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:177,402,904...177,447,047
Ensembl chr 4:177,402,904...177,447,028 		JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions		 ISO panobinostat results in increased expression of ETS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625 		JBrowse link
G Etv1 ETS variant transcription factor 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA
panobinostat results in decreased expression of ETV1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:58,467,215...58,558,640
Ensembl chr 6:58,467,254...58,558,631 		JBrowse link
G Ext1 exostosin glycosyltransferase 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA
panobinostat results in decreased expression of EXT1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:92,605,008...92,881,392
Ensembl chr 7:92,605,728...92,882,068 		JBrowse link
G Ezr ezrin multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA
panobinostat results in increased expression of EZR mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412 		JBrowse link
G F2rl1 F2R like trypsin receptor 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA
panobinostat results in increased expression of F2RL1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275 		JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA
panobinostat results in decreased expression of F2RL2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:26,240,385...26,245,533
Ensembl chr 2:26,240,385...26,245,533 		JBrowse link
G Fabp3 fatty acid binding protein 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA
panobinostat results in increased expression of FABP3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565 		JBrowse link
G Fam110b family with sequence similarity 110, member B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA CTD PMID:27188386 NCBI chr 5:18,762,488...18,903,818
Ensembl chr 5:18,901,039...18,902,672 		JBrowse link
G Fam124a family with sequence similarity 124 member A decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of FAM124A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:45,711,994...45,780,395
Ensembl chr15:45,712,821...45,780,405 		JBrowse link
G Fam13c family with sequence similarity 13, member C multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA
panobinostat results in increased expression of FAM13C mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:19,358,869...19,470,212
Ensembl chr20:19,360,230...19,479,325 		JBrowse link
G Fam149a family with sequence similarity 149, member A decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of FAM149A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:50,049,816...50,105,962
Ensembl chr16:50,049,828...50,107,856 		JBrowse link
G Fam155a family with sequence similarity 155, member A multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM155A mRNA
panobinostat results in decreased expression of FAM155A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:85,528,126...86,053,447 JBrowse link
G Fam163a family with sequence similarity 163, member A affects expression
multiple interactions		 ISO panobinostat affects the expression of FAM163A mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAM163A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAM163A mRNA]		 CTD PMID:26733615 NCBI chr13:73,741,674...73,820,114
Ensembl chr13:73,741,679...73,819,896 		JBrowse link
G Fam168a family with sequence similarity 168, member A decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of FAM168A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:165,723,278...165,880,612
Ensembl chr 1:165,724,451...165,878,652 		JBrowse link
G Fam241a family with sequence similarity 241 member A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA CTD PMID:27188386 NCBI chr 2:232,214,331...232,245,319
Ensembl chr 2:232,214,331...232,245,319 		JBrowse link
G Fam43a family with sequence similarity 43, member A increases expression
multiple interactions		 ISO panobinostat results in increased expression of FAM43A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:73,676,601...73,679,003
Ensembl chr11:73,676,601...73,678,984 		JBrowse link
G Fam71f1 family with sequence similarity 71, member F1 decreases expression ISO panobinostat results in decreased expression of FAM71F1 mRNA CTD PMID:26272509 NCBI chr 4:56,591,719...56,615,157
Ensembl chr 4:56,591,715...56,615,158 		JBrowse link
G Fam89a family with sequence similarity 89, member A increases expression
multiple interactions		 ISO panobinostat results in increased expression of FAM89A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:57,502,308...57,514,896
Ensembl chr19:57,502,308...57,514,896 		JBrowse link
G Fank1 fibronectin type III and ankyrin repeat domains 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA
panobinostat results in decreased expression of FANK1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:205,842,469...205,954,152
Ensembl chr 1:205,842,489...205,950,371 		JBrowse link
G Fat3 FAT atypical cadherin 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of FAT3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:14,417,039...15,011,596
Ensembl chr 8:14,417,584...14,880,644 		JBrowse link
G Faxc failed axon connections homolog, metaxin like GST domain containing affects expression
multiple interactions		 ISO panobinostat affects the expression of FAXC mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAXC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAXC mRNA]		 CTD PMID:26733615 NCBI chr 5:36,076,565...36,135,884
Ensembl chr 5:36,076,565...36,135,884 		JBrowse link
G Fbln7 fibulin 7 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of FBLN7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:121,407,981...121,441,660
Ensembl chr 3:121,408,146...121,440,787 		JBrowse link
G Fbn1 fibrillin 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA
panobinostat results in decreased expression of FBN1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120 		JBrowse link
G Fbxl13 F-box and leucine-rich repeat protein 13 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA CTD PMID:27188386 NCBI chr 4:10,020,349...10,170,012
Ensembl chr 4:10,020,349...10,167,023 		JBrowse link
G Fbxo2 F-box protein 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FBXO2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:164,972,483...164,977,912
Ensembl chr 5:164,972,480...164,977,916 		JBrowse link
G Fbxo8 F-box protein 8 multiple interactions
affects expression		 ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FBXO8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FBXO8 mRNA] CTD PMID:26733615 NCBI chr16:37,131,566...37,177,033
Ensembl chr16:37,131,345...37,177,033 		JBrowse link
G Fbxo9 f-box protein 9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA CTD PMID:27188386 NCBI chr 8:85,388,331...85,413,896
Ensembl chr 8:85,388,333...85,413,484 		JBrowse link
G Fermt1 fermitin family member 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FERMT1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:125,566,744...125,607,864
Ensembl chr 3:125,566,643...125,607,735 		JBrowse link
G Fez1 fasciculation and elongation protein zeta 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA
panobinostat results in decreased expression of FEZ1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270 		JBrowse link
G Fezf2 Fez family zinc finger 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA
panobinostat results in decreased expression of FEZF2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:12,825,333...12,831,496
Ensembl chr15:12,827,707...12,831,496 		JBrowse link
G Fgd5 FYVE, RhoGEF and PH domain containing 5 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA
panobinostat results in increased expression of FGD5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:123,865,557...123,962,904
Ensembl chr 4:123,865,725...123,962,881 		JBrowse link
G Fgf18 fibroblast growth factor 18 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA CTD PMID:27188386 NCBI chr10:18,047,109...18,082,290
Ensembl chr10:18,047,109...18,063,391 		JBrowse link
G Fgf19 fibroblast growth factor 19 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FGF19 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693 		JBrowse link
G Fgf8 fibroblast growth factor 8 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of FGF8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831 		JBrowse link
G Fgf9 fibroblast growth factor 9 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of FGF9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316 		JBrowse link
G Fgfbp3 fibroblast growth factor binding protein 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FGFBP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:255,555,050...255,557,055
Ensembl chr 1:255,555,050...255,557,055 		JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA
panobinostat results in increased expression of FGFR3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706 		JBrowse link
G Fhod3 formin homology 2 domain containing 3 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA
panobinostat results in decreased expression of FHOD3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:16,650,786...17,332,209
Ensembl chr18:16,650,806...17,332,210 		JBrowse link
G Fign fidgetin, microtubule severing factor affects expression
multiple interactions		 ISO panobinostat affects the expression of FIGN mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FIGN mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FIGN mRNA]		 CTD PMID:26733615 NCBI chr 3:49,992,250...50,120,601
Ensembl chr 3:49,992,397...50,120,392 		JBrowse link
G Fjx1 four-jointed box kinase 1 decreases expression ISO panobinostat results in decreased expression of FJX1 mRNA CTD PMID:26272509 NCBI chr 3:92,288,818...92,290,919
Ensembl chr 3:92,288,818...92,290,919 		JBrowse link
G Flnb filamin B increases expression ISO panobinostat results in increased expression of FLNB mRNA CTD PMID:26272509 NCBI chr15:18,750,152...18,883,019
Ensembl chr15:18,750,118...18,883,005 		JBrowse link
G Flrt2 fibronectin leucine rich transmembrane protein 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA
panobinostat results in decreased expression of FLRT2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:119,518,459...119,613,534
Ensembl chr 6:119,519,714...119,609,296 		JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA
panobinostat results in increased expression of FLT1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905 		JBrowse link
G Fndc5 fibronectin type III domain containing 5 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA
panobinostat results in decreased expression of FNDC5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:147,323,240...147,330,266
Ensembl chr 5:147,323,240...147,330,266 		JBrowse link
G Foxc1 forkhead box C1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FOXC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:33,947,501...33,951,484
Ensembl chr17:33,947,506...33,951,484 		JBrowse link
G Foxc2 forkhead box C2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FOXC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:53,044,379...53,047,081
Ensembl chr19:53,044,379...53,047,081 		JBrowse link
G Foxd3 forkhead box D3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FOXD3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:118,346,283...118,349,120 JBrowse link
G Foxh1 forkhead box H1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FOXH1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:117,730,307...117,733,076
Ensembl chr 7:117,730,307...117,732,387 		JBrowse link
G Foxo1 forkhead box O1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of FOXO1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016 		JBrowse link
G Fras1 Fraser extracellular matrix complex subunit 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of FRAS1 mRNA CTD PMID:21791302 NCBI chr14:14,438,392...14,853,016
Ensembl chr14:14,439,082...14,689,554 		JBrowse link
G Frem1 Fras1 related extracellular matrix 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA
panobinostat results in increased expression of FREM1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:101,018,009...101,166,794
Ensembl chr 5:101,020,448...101,166,651 		JBrowse link
G Frrs1l ferric-chelate reductase 1-like multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA
panobinostat results in decreased expression of FRRS1L mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:73,997,958...74,029,381
Ensembl chr 5:74,000,227...74,029,238 		JBrowse link
G Frzb frizzled-related protein multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA
panobinostat results in decreased expression of FRZB mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:67,635,604...67,668,772
Ensembl chr 3:67,635,607...67,668,772 		JBrowse link
G Fut4 fucosyltransferase 4 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA
panobinostat results in increased expression of FUT4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:13,258,768...13,262,729
Ensembl chr 8:13,258,768...13,262,729 		JBrowse link
G Fut9 fucosyltransferase 9 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA
panobinostat results in decreased expression of FUT9 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:40,032,855...40,237,591
Ensembl chr 5:40,032,855...40,237,591 		JBrowse link
G Fzd10 frizzled class receptor 10 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA
panobinostat results in increased expression of FZD10 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr12:31,757,407...31,760,604
Ensembl chr12:31,757,407...31,760,604 		JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA
panobinostat results in decreased expression of FZD2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057 		JBrowse link
G Fzd3 frizzled class receptor 3 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA
panobinostat results in decreased expression of FZD3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:48,601,259...48,670,257
Ensembl chr15:48,601,266...48,670,257 		JBrowse link
G Fzd5 frizzled class receptor 5 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA
panobinostat results in decreased expression of FZD5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:71,443,784...71,445,541
Ensembl chr 9:71,443,588...71,445,739 		JBrowse link
G Fzd7 frizzled class receptor 7 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA
panobinostat results in increased expression of FZD7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550 		JBrowse link
G Fzd8 frizzled class receptor 8 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA CTD PMID:27188386 NCBI chr17:62,259,910...62,267,239
Ensembl chr17:62,262,129...62,265,113 		JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA
panobinostat results in increased expression of GABRB2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:27,973,694...28,193,072
Ensembl chr10:27,973,681...28,187,565 		JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
panobinostat results in increased expression of GABRB3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:113,034,251...113,265,364
Ensembl chr 1:112,976,770...113,265,364 		JBrowse link
G Gabrp gamma-aminobutyric acid type A receptor subunit pi multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA CTD PMID:27188386 NCBI chr10:18,484,257...18,510,604
Ensembl chr10:18,485,514...18,506,337 		JBrowse link
G Gad1 glutamate decarboxylase 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA
panobinostat results in increased expression of GAD1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157 		JBrowse link
G Gad2 glutamate decarboxylase 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA CTD PMID:27188386 NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; Panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45A mRNA]; SRT2183 promotes the reaction [Panobinostat results in increased expression of GADD45A mRNA]
panobinostat results in increased expression of GADD45A mRNA		 CTD PMID:23681230, PMID:26272509, PMID:27188386 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions		 ISO panobinostat results in increased expression of GADD45B mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322 		JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma multiple interactions
increases expression		 ISO GADD45G protein affects the susceptibility to [SRT2183 co-treated with panobinostat]; panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; panobinostat promotes the reaction [resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [resveratrol results in increased expression of GADD45G mRNA]; panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45G mRNA]; resveratrol promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]; SRT2183 promotes the reaction [panobinostat results in increased expression of GADD45G mRNA] CTD PMID:23681230 NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243 		JBrowse link
G Galnt18 polypeptide N-acetylgalactosaminyltransferase 18 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA
panobinostat results in increased expression of GALNT18 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:176,296,186...176,607,466
Ensembl chr 1:176,296,193...176,607,466 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
panobinostat results in increased expression of GALNT3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:52,174,469...52,212,395
Ensembl chr 3:52,175,547...52,212,412 		JBrowse link
G Gap43 growth associated protein 43 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA
panobinostat results in increased expression of GAP43 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914 		JBrowse link
G Gas7 growth arrest specific 7 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA
panobinostat results in increased expression of GAS7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:54,010,723...54,240,805
Ensembl chr10:54,126,486...54,236,476 		JBrowse link
G Gata2 GATA binding protein 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA
panobinostat results in increased expression of GATA2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488 		JBrowse link
G Gata3 GATA binding protein 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
panobinostat results in increased expression of GATA3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681 		JBrowse link
G Gata4 GATA binding protein 4 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA
panobinostat results in decreased expression of GATA4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:46,386,703...46,458,679
Ensembl chr15:46,386,712...46,432,965 		JBrowse link
G Gata6 GATA binding protein 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA CTD PMID:27188386 NCBI chr18:2,415,821...2,447,087
Ensembl chr18:2,416,552...2,446,338 		JBrowse link
G Gbx2 gastrulation brain homeobox 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of GBX2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:97,063,265...97,065,855
Ensembl chr 9:97,063,728...97,065,817 		JBrowse link
G Gchfr GTP cyclohydrolase I feedback regulator increases expression
multiple interactions		 ISO panobinostat results in increased expression of GCHFR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:110,975,923...110,979,957
Ensembl chr 3:110,975,923...110,979,957 		JBrowse link
G Gdf10 growth differentiation factor 10 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA CTD PMID:27188386 NCBI chr16:10,250,508...10,262,383
Ensembl chr16:10,250,404...10,263,150 		JBrowse link
G Gja3 gap junction protein, alpha 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of GJA3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:37,298,607...37,325,370
Ensembl chr15:37,299,738...37,325,178 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA CTD PMID:27188386 NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277 		JBrowse link
G Gje1 gap junction protein, epsilon 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GJE1 mRNA CTD PMID:21791302 NCBI chr 1:8,883,767...8,887,721
Ensembl chr 1:8,883,961...8,885,967 		JBrowse link
G Gkap1 G kinase anchoring protein 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA
panobinostat results in decreased expression of GKAP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:6,785,428...6,825,145
Ensembl chr17:6,785,428...6,825,144 		JBrowse link
G Glb1l galactosidase, beta 1-like multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GLB1L mRNA CTD PMID:21791302 NCBI chr 9:82,400,457...82,410,970
Ensembl chr 9:82,400,569...82,410,904 		JBrowse link
G Glcci1 glucocorticoid induced 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of GLCCI1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:34,282,625...34,612,709
Ensembl chr 4:34,282,625...34,614,438 		JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:246,380,816...246,564,385
Ensembl chr 1:246,380,889...246,785,360 		JBrowse link
G Glrx2 glutaredoxin 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA
panobinostat results in increased expression of GLRX2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:60,529,057...60,552,115
Ensembl chr13:60,529,932...60,537,916 		JBrowse link
G Gls glutaminase multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA
panobinostat results in increased expression of GLS mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872 		JBrowse link
G Gnas GNAS complex locus multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA
panobinostat results in increased expression of GNAS mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:172,374,957...172,434,988
Ensembl chr 3:172,374,957...172,428,483
Ensembl chr 3:172,374,957...172,428,483 		JBrowse link
G Gng11 G protein subunit gamma 11 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA
panobinostat results in increased expression of GNG11 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:28,989,170...28,994,610
Ensembl chr 4:28,989,115...28,993,621 		JBrowse link
G Gng8 G protein subunit gamma 8 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA
panobinostat results in decreased expression of GNG8 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:78,818,360...78,822,224
Ensembl chr 1:78,818,404...78,822,224 		JBrowse link
G Gnl3l G protein nucleolar 3 like multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA CTD PMID:21791302 NCBI chr  X:20,037,558...20,070,505
Ensembl chr  X:20,034,882...20,070,578 		JBrowse link
G Gpc3 glypican 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of GPC3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:139,579,268...139,947,093
Ensembl chr  X:139,579,268...139,916,883 		JBrowse link
G Gpc4 glypican 4 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of GPC4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:139,354,325...139,464,876
Ensembl chr  X:139,354,155...139,464,798 		JBrowse link
G Gpc6 glypican 6 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA
panobinostat results in decreased expression of GPC6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:102,164,091...103,174,721
Ensembl chr15:102,164,751...103,170,847 		JBrowse link
G Gpd1l glycerol-3-phosphate dehydrogenase 1-like increases expression
multiple interactions		 ISO panobinostat results in increased expression of GPD1L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:122,957,570...122,987,236
Ensembl chr 8:122,954,948...122,987,191 		JBrowse link
G Gpr173 G-protein coupled receptor 173 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of GPR173 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:22,417,753...22,418,873
Ensembl chr  X:22,417,753...22,418,873 		JBrowse link
G Gpr27 G protein-coupled receptor 27 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of GPR27 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:132,137,793...132,138,926
Ensembl chr 4:132,137,793...132,138,926 		JBrowse link
G Gpr37 G protein-coupled receptor 37 increases expression
multiple interactions		 ISO panobinostat results in increased expression of GPR37 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:51,822,163...51,844,228
Ensembl chr 4:51,822,153...51,844,331 		JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions		 ISO panobinostat results in increased expression of GREM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:105,203,309...105,214,989
Ensembl chr 3:105,203,309...105,214,989 		JBrowse link
G Grhl1 grainyhead-like transcription factor 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA CTD PMID:27188386 NCBI chr 6:43,734,837...43,795,757
Ensembl chr 6:43,743,702...43,794,342 		JBrowse link
G Grhl2 grainyhead-like transcription factor 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA CTD PMID:27188386 NCBI chr 7:76,058,623...76,197,360
Ensembl chr 7:76,059,386...76,197,856 		JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of GRHL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:153,893,039...153,925,045
Ensembl chr 5:153,893,039...153,924,896 		JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA CTD PMID:27188386 NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200 		JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:127,561,843...127,829,763
Ensembl chr  X:127,562,660...127,829,753 		JBrowse link
G Grik3 glutamate ionotropic receptor kainate type subunit 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of GRIK3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:143,500,441...143,715,546
Ensembl chr 5:143,500,441...143,715,546 		JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA CTD PMID:27188386 NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990 		JBrowse link
G Grm3 glutamate metabotropic receptor 3 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA
panobinostat results in decreased expression of GRM3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:21,316,761...21,567,561
Ensembl chr 4:21,317,695...21,560,490 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA1 mRNA CTD PMID:21791302 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA2 mRNA CTD PMID:21791302 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gsta5 glutathione S-transferase alpha 5 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA5 mRNA CTD PMID:21791302 NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179 		JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions
affects expression		 ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of GUCY1A1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of GUCY1A1 mRNA] CTD PMID:26733615 NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918 		JBrowse link
G Gypc glycophorin C (Gerbich blood group) increases expression
multiple interactions		 ISO panobinostat results in increased expression of GYPC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:25,312,386...25,344,614
Ensembl chr18:25,312,387...25,344,614 		JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression		 ISO manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]]; Panobinostat promotes the reaction [SRT2183 results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein] CTD PMID:22923501, PMID:23681230 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981 		JBrowse link
G H2bc12 H2B clustered histone 12 decreases expression
multiple interactions		 ISO Panobinostat results in decreased expression of H2BC12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:44,527,421...44,527,801
Ensembl chr17:44,527,421...44,527,801 		JBrowse link
G H3f4 H3.4 histone increases acetylation ISO Panobinostat results in increased acetylation of H3-4 protein CTD PMID:19215824 NCBI chr10:45,304,696...45,305,106 JBrowse link
G Hacd1 3-hydroxyacyl-CoA dehydratase 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of HACD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:81,173,238...81,196,012
Ensembl chr17:81,173,713...81,187,739 		JBrowse link
G Hand1 heart and neural crest derivatives expressed 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA CTD PMID:27188386 NCBI chr10:43,250,729...43,253,296
Ensembl chr10:43,250,745...43,253,296 		JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
panobinostat results in increased expression of HAPLN1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:18,354,542...18,419,077
Ensembl chr 2:18,354,542...18,419,071 		JBrowse link
G Has2 hyaluronan synthase 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA
panobinostat results in increased expression of HAS2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:96,438,046...96,464,049
Ensembl chr 7:96,438,046...96,464,049 		JBrowse link
G Hck HCK proto-oncogene, Src family tyrosine kinase multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA CTD PMID:27188386 NCBI chr 3:148,579,917...148,623,026
Ensembl chr 3:148,579,920...148,623,033 		JBrowse link
G Hdac8 histone deacetylase 8 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA
panobinostat results in increased expression of HDAC8 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:72,163,777...72,370,058
Ensembl chr  X:72,163,777...72,370,044 		JBrowse link
G Hdac9 histone deacetylase 9 decreases expression ISO Panobinostat results in decreased expression of HDAC9 mRNA CTD PMID:30481203 NCBI chr 6:53,487,367...54,358,694
Ensembl chr 6:53,488,883...54,059,119 		JBrowse link
G Heg1 heart development protein with EGF-like domains 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA
panobinostat results in decreased expression of HEG1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:70,234,248...70,322,966
Ensembl chr11:70,236,888...70,322,690 		JBrowse link
G Hes2 hes family bHLH transcription factor 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of HES2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:169,338,097...169,339,142
Ensembl chr 5:169,338,097...169,339,142 		JBrowse link
G Hes5 hes family bHLH transcription factor 5 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of HES5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:172,364,421...172,365,188
Ensembl chr 5:172,364,421...172,365,188 		JBrowse link
G Hesx1 HESX homeobox 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of HESX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:2,616,538...2,636,708
Ensembl chr16:2,634,603...2,636,708 		JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA
panobinostat results in increased expression of HEY2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:29,191,170...29,201,257
Ensembl chr 1:29,191,192...29,201,531 		JBrowse link
G Hhip Hedgehog-interacting protein multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA CTD PMID:27188386 NCBI chr19:31,525,134...31,614,487
Ensembl chr19:31,524,671...31,614,246 		JBrowse link
G Hk1 hexokinase 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of HK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:31,911,460...31,979,780
Ensembl chr20:31,912,262...31,956,649 		JBrowse link
G Hmgcll1 3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of HMGCLL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:83,069,837...83,204,778
Ensembl chr 8:83,070,545...83,205,441 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA
panobinostat results in increased expression of HMOX1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456 		JBrowse link
G Hmx2 H6 family homeobox 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA CTD PMID:27188386 NCBI chr 1:203,515,605...203,523,266
Ensembl chr 1:203,515,609...203,523,358 		JBrowse link
G Hnmt histamine N-methyltransferase increases expression
multiple interactions		 ISO panobinostat results in increased expression of HNMT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:905,111...937,038
Ensembl chr 3:904,765...937,102 		JBrowse link
G Hnrnpr heterogeneous nuclear ribonucleoprotein R multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA CTD PMID:27188386 NCBI chr 5:154,668,194...154,699,967
Ensembl chr 5:154,668,179...154,699,966 		JBrowse link
G Homez homeobox and leucine zipper encoding multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA CTD PMID:27188386 NCBI chr15:33,510,454...33,528,018
Ensembl chr15:33,510,458...33,527,031 		JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA CTD PMID:27188386 NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066 		JBrowse link
G Hpdl 4-hydroxyphenylpyruvate dioxygenase-like multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA
panobinostat results in increased expression of HPDL mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:135,675,826...135,677,432
Ensembl chr 5:135,675,832...135,677,432 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA CTD PMID:27188386 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758 		JBrowse link
G Hps1 HPS1, biogenesis of lysosomal organelles complex 3 subunit 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA
panobinostat results in increased expression of HPS1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:261,989,178...262,015,282
Ensembl chr 1:261,989,178...262,015,153 		JBrowse link
G Hrk harakiri, BCL2 interacting protein increases expression
multiple interactions		 ISO panobinostat results in increased expression of HRK mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr12:44,008,879...44,029,211 JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:50,369,097...50,402,584
Ensembl chr10:50,366,952...50,402,616 		JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression
multiple interactions		 ISO panobinostat results in increased expression of HSPA4L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:127,625,737...127,682,864
Ensembl chr 2:127,625,683...127,677,503 		JBrowse link
G Hspb11 heat shock protein family B (small), member 11 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSPB11 mRNA
panobinostat results in decreased expression of HSPB11 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:126,856,128...126,882,913
Ensembl chr 5:126,856,705...126,882,909 		JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ICAM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059 		JBrowse link
G Id4 inhibitor of DNA binding 4, HLH protein multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA
panobinostat results in increased expression of ID4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:16,692,557...16,695,126
Ensembl chr17:16,692,557...16,695,126 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA
panobinostat results in increased expression of IDH3A mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908 		JBrowse link
G Ier3 immediate early response 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of IER3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769 		JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA
panobinostat results in increased expression of IFI30 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:20,426,566...20,430,772
Ensembl chr16:20,426,566...20,430,752 		JBrowse link
G Ifnar2 interferon alpha and beta receptor subunit 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of IFNAR2 mRNA CTD PMID:21791302 NCBI chr11:31,527,790...31,559,834
Ensembl chr11:31,539,016...31,558,851 		JBrowse link
G Igdcc3 immunoglobulin superfamily, DCC subclass, member 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of IGDCC3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:70,630,546...70,685,882
Ensembl chr 8:70,630,767...70,684,115 		JBrowse link
G Igf2 insulin-like growth factor 2 increases expression ISO panobinostat results in increased expression of IGF2 mRNA CTD PMID:26272509 NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases expression ISO panobinostat results in decreased expression of IGFBP3 mRNA CTD PMID:26272509 NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374 		JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA
panobinostat results in increased expression of IGFBP7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:33,010,300...33,070,193
Ensembl chr14:33,010,300...33,070,190 		JBrowse link
G Igsf21 immunoglobin superfamily, member 21 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA CTD PMID:27188386 NCBI chr 5:158,503,090...158,735,702
Ensembl chr 5:158,503,244...158,549,496 		JBrowse link
G Il17rd interleukin 17 receptor D decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of IL17RD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:2,670,471...2,737,271
Ensembl chr16:2,670,618...2,731,808 		JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of IL1RAPL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:55,439,388...57,004,865
Ensembl chr  X:55,439,578...56,765,893 		JBrowse link
G Il20rb interleukin 20 receptor subunit beta increases expression
multiple interactions		 ISO panobinostat results in increased expression of IL20RB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:108,745,906...108,778,561
Ensembl chr 8:108,747,204...108,777,717 		JBrowse link
G Il27ra interleukin 27 receptor subunit alpha increases expression
multiple interactions		 ISO panobinostat results in increased expression of IL27RA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:25,151,835...25,163,995
Ensembl chr19:25,149,897...25,164,086 		JBrowse link
G Il3ra interleukin 3 receptor subunit alpha multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of IL3RA mRNA CTD PMID:21791302 NCBI chr12:18,534,762...18,542,508
Ensembl chr12:18,534,767...18,540,166 		JBrowse link
G Inf2 inverted formin 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA
panobinostat results in increased expression of INF2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:137,162,593...137,180,198
Ensembl chr 6:137,164,535...137,177,622 		JBrowse link
G Inhbe inhibin subunit beta E multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA
panobinostat results in increased expression of INHBE mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169 		JBrowse link
G Inpp4b inositol polyphosphate-4-phosphatase type II B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA CTD PMID:27188386 NCBI chr19:29,592,889...30,341,528
Ensembl chr19:29,597,905...29,968,424 		JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA CTD PMID:27188386 NCBI chr 9:94,745,220...94,850,778
Ensembl chr 9:94,745,217...94,850,771 		JBrowse link
G Insc INSC, spindle orientation adaptor protein increases expression
multiple interactions		 ISO panobinostat results in increased expression of INSC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:184,299,200...184,407,487
Ensembl chr 1:184,299,250...184,407,480 		JBrowse link
G Iqca1 IQ motif containing with AAA domain 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQCA1 mRNA
panobinostat results in increased expression of IQCA1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:97,190,240...97,298,760 JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA
panobinostat results in increased expression of IQGAP1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:142,525,041...142,615,673
Ensembl chr 1:142,525,046...142,615,673 		JBrowse link
G Irf6 interferon regulatory factor 6 increases expression
multiple interactions		 ISO panobinostat results in increased expression of IRF6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:111,870,121...111,889,328
Ensembl chr13:111,870,121...111,889,328 		JBrowse link
G Irx1 iroquois homeobox 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA
panobinostat results in increased expression of IRX1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:33,910,912...33,916,741
Ensembl chr 1:33,910,912...33,916,741 		JBrowse link
G Irx2 iroquois homeobox 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA
panobinostat results in increased expression of IRX2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:33,270,388...33,275,868
Ensembl chr 1:33,271,977...33,275,540 		JBrowse link
G Irx3 iroquois homeobox 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA
panobinostat results in increased expression of IRX3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:15,838,714...15,842,135
Ensembl chr19:15,838,714...15,840,990 		JBrowse link
G Isl1 ISL LIM homeobox 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA CTD PMID:27188386 NCBI chr 2:48,488,911...48,501,217
Ensembl chr 2:48,487,736...48,501,436 		JBrowse link
G Itga8 integrin subunit alpha 8 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ITGA8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:79,321,893...79,676,927
Ensembl chr17:79,321,900...79,676,499 		JBrowse link
G Itga9 integrin subunit alpha 9 increases expression
multiple interactions		 ISO panobinostat results in increased expression of ITGA9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:127,271,029...127,576,709
Ensembl chr 8:127,271,289...127,572,988 		JBrowse link
G Itgb5 integrin subunit beta 5 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of ITGB5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372 		JBrowse link
G Itm2a integral membrane protein 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA CTD PMID:27188386 NCBI chr  X:78,490,872...78,496,814
Ensembl chr  X:78,490,866...78,496,847 		JBrowse link
G Itpr2 inositol 1,4,5-trisphosphate receptor, type 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA
panobinostat results in increased expression of ITPR2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:180,423,452...180,800,088
Ensembl chr 4:180,538,389...180,722,358 		JBrowse link
G Jade2 jade family PHD finger 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of JADE2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:37,269,132...37,315,638
Ensembl chr10:37,270,183...37,311,625 		JBrowse link
G Jazf1 JAZF zinc finger 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of JAZF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:82,834,181...83,141,430
Ensembl chr 4:82,836,260...83,137,527 		JBrowse link
G Jcad junctional cadherin 5 associated increases expression
multiple interactions		 ISO panobinostat results in increased expression of JCAD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:55,667,754...55,709,738
Ensembl chr17:55,670,331...55,709,740 		JBrowse link
G Jdp2 Jun dimerization protein 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of JDP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:109,464,910...109,505,591
Ensembl chr 6:109,466,060...109,505,161 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO panobinostat results in increased expression of JUN mRNA CTD PMID:26272509 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277 		JBrowse link
G Kank4 KN motif and ankyrin repeat domains 4 increases expression
multiple interactions		 ISO panobinostat results in increased expression of KANK4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:117,376,425...117,440,643
Ensembl chr 5:117,376,423...117,440,254 		JBrowse link
G Kat2b lysine acetyltransferase 2B multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA
panobinostat results in decreased expression of KAT2B mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:4,440,982...4,492,949 JBrowse link
G Kat6a lysine acetyltransferase 6A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA CTD PMID:27188386 NCBI chr16:73,942,669...74,020,750
Ensembl chr16:73,943,455...74,023,005 		JBrowse link
G Kat7 lysine acetyltransferase 7 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA
panobinostat results in decreased expression of KAT7 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:83,095,067...83,128,342
Ensembl chr10:83,095,068...83,128,297 		JBrowse link
G Kbtbd11 kelch repeat and BTB domain containing 11 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of KBTBD11 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:79,696,395...79,716,129
Ensembl chr16:79,696,891...79,700,992 		JBrowse link
G Kcna7 potassium voltage-gated channel subfamily A member 7 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KCNA7 mRNA CTD PMID:21791302 NCBI chr 1:101,397,828...101,403,320
Ensembl chr 1:101,397,828...101,403,320 		JBrowse link
G Kcnc1 potassium voltage-gated channel subfamily C member 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA
panobinostat results in decreased expression of KCNC1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:102,414,352...102,456,718
Ensembl chr 1:102,414,625...102,456,411 		JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
panobinostat results in decreased expression of KCND2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:48,309,283...48,816,804 JBrowse link
G Kcng1 potassium voltage-gated channel modifier subfamily G member 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of KCNG1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:165,020,230...165,040,966
Ensembl chr 3:165,020,230...165,039,707 		JBrowse link
G Kcnh5 potassium voltage-gated channel subfamily H member 5 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA
panobinostat results in decreased expression of KCNH5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:97,872,831...98,157,087
Ensembl chr 6:97,872,831...98,157,087 		JBrowse link
G Kcnj13 potassium inwardly-rectifying channel, subfamily J, member 13 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA
panobinostat results in decreased expression of KCNJ13 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:94,486,719...94,495,333
Ensembl chr 9:94,487,224...94,495,333 		JBrowse link
G Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA CTD PMID:27188386 NCBI chr 3:41,019,898...41,181,070
Ensembl chr 3:41,019,898...41,181,070 		JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA CTD PMID:27188386 NCBI chr19:58,823,836...58,862,926
Ensembl chr19:58,823,814...58,862,926 		JBrowse link
G Kcnk10 potassium two pore domain channel subfamily K member 10 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA
panobinostat results in decreased expression of KCNK10 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:122,417,079...122,549,532
Ensembl chr 6:122,419,046...122,545,899 		JBrowse link
G Kcnmb4 potassium calcium-activated channel subfamily M regulatory beta subunit 4 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KCNMB4 mRNA CTD PMID:21791302 NCBI chr 7:59,461,808...59,514,759
Ensembl chr 7:59,461,799...59,514,939 		JBrowse link
G Kcnn3 potassium calcium-activated channel subfamily N member 3 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA
panobinostat results in decreased expression of KCNN3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:188,837,280...188,991,794
Ensembl chr 2:188,844,073...188,988,774 		JBrowse link
G Kcnv1 potassium voltage-gated channel modifier subfamily V member 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA CTD PMID:27188386 NCBI chr 7:84,016,864...84,023,205
Ensembl chr 7:84,015,207...84,023,316 		JBrowse link
G Kctd1 potassium channel tetramerization domain containing 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA
panobinostat results in increased expression of KCTD1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:6,374,778...6,474,990
Ensembl chr18:6,374,778...6,474,990 		JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA
panobinostat results in increased expression of KCTD12 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:87,384,632...87,390,627 JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA CTD PMID:27188386 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183 		JBrowse link
G Kif13a kinesin family member 13A decreases expression ISO panobinostat results in decreased expression of KIF13A mRNA CTD PMID:26272509 NCBI chr17:18,151,582...18,335,027
Ensembl chr17:18,151,982...18,335,019 		JBrowse link
G Kif28p kinesin family member 28, pseudogene multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA CTD PMID:27188386 NCBI chr13:97,969,335...98,023,829
Ensembl chr13:97,969,335...98,023,829 		JBrowse link
G Kif5c kinesin family member 5C multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KIF5C mRNA CTD PMID:21791302 NCBI chr 3:35,014,157...35,257,417
Ensembl chr 3:35,014,538...35,257,407 		JBrowse link
G Kifap3 kinesin-associated protein 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of KIFAP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:82,072,497...82,217,256
Ensembl chr13:82,072,497...82,217,252 		JBrowse link
G Kiss1r KISS1 receptor multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA CTD PMID:27188386 NCBI chr 7:12,606,210...12,609,868
Ensembl chr 7:12,606,210...12,609,868 		JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase increases expression
multiple interactions		 ISO panobinostat results in increased expression of KIT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610 		JBrowse link
G Kitlg KIT ligand increases expression
multiple interactions		 ISO panobinostat results in increased expression of KITLG mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054 		JBrowse link
G Kiz kizuna centrosomal protein decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of KIZ mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:141,067,981...141,173,738
Ensembl chr 3:141,068,023...141,173,858 		JBrowse link
G Klf15 Kruppel-like factor 15 increases expression
multiple interactions		 ISO panobinostat results in increased expression of KLF15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:122,364,688...122,377,690
Ensembl chr 4:122,365,093...122,377,659 		JBrowse link
G Klf4 Kruppel like factor 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA CTD PMID:27188386 NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669 		JBrowse link
G Klf5 Kruppel-like factor 5 increases expression
multiple interactions		 ISO panobinostat results in increased expression of KLF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921 		JBrowse link
G Klf6 Kruppel-like factor 6 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA
panobinostat results in increased expression of KLF6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037 		JBrowse link
G Klhl14 kelch-like family member 14 increases expression ISO panobinostat results in increased expression of KLHL14 mRNA CTD PMID:26272509 NCBI chr18:12,526,627...12,640,381
Ensembl chr18:12,528,111...12,640,716 		JBrowse link
G Klk10 kallikrein related-peptidase 10 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA CTD PMID:21791302 NCBI chr 1:99,718,275...99,722,743
Ensembl chr 1:99,718,907...99,722,284 		JBrowse link
G Klk8 kallikrein related-peptidase 8 multiple interactions
increases expression		 ISO [Cisplatin co-treated with Panobinostat] affects the expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA
panobinostat results in increased expression of KLK8 mRNA		 CTD PMID:21791302, PMID:26272509, PMID:27188386 NCBI chr 1:99,735,168...99,742,011
Ensembl chr 1:99,734,993...99,742,009 		JBrowse link
G Klrg2 killer cell lectin like receptor G2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of KLRG2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:66,370,674...66,381,351
Ensembl chr 4:66,371,511...66,380,734 		JBrowse link
G Kremen1 kringle containing transmembrane protein 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of KREMEN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:85,441,209...85,503,661
Ensembl chr14:85,438,707...85,484,275 		JBrowse link
G Krt18 keratin 18 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA
panobinostat results in increased expression of KRT18 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131 		JBrowse link
G Krt19 keratin 19 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA CTD PMID:27188386 NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561 		JBrowse link
G Krt8 keratin 8 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA
panobinostat results in increased expression of KRT8 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803 		JBrowse link
G L1cam L1 cell adhesion molecule multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA
panobinostat results in increased expression of L1CAM mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:156,901,244...156,928,064
Ensembl chr  X:156,909,913...156,928,057 		JBrowse link
G L1td1 LINE-1 type transposase domain containing 1 increases expression ISO panobinostat results in increased expression of L1TD1 mRNA CTD PMID:26272509 NCBI chr 5:117,347,998...117,361,012
Ensembl chr 5:117,354,794...117,360,654 		JBrowse link
G Lacc1 laccase domain containing 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LACC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:59,199,537...59,217,200
Ensembl chr15:59,209,829...59,215,803 		JBrowse link
G Lactb lactamase, beta increases expression
multiple interactions		 ISO panobinostat results in increased expression of LACTB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:72,750,174...72,766,307
Ensembl chr 8:72,750,171...72,766,389 		JBrowse link
G Lama2 laminin subunit alpha 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LAMA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:18,491,264...19,143,486
Ensembl chr 1:18,491,384...19,143,269 		JBrowse link
G Lama4 laminin subunit alpha 4 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LAMA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr20:44,060,715...44,201,966
Ensembl chr20:44,060,731...44,209,614 		JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LAMC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252 		JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LAMP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:124,722,628...124,766,079
Ensembl chr  X:124,722,628...124,766,044 		JBrowse link
G Layn layilin increases expression
multiple interactions		 ISO panobinostat results in increased expression of LAYN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:55,447,203...55,469,420
Ensembl chr 8:55,447,709...55,467,688 		JBrowse link
G Lctl lactase-like decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of LCTL mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:69,070,340...69,090,405
Ensembl chr 8:69,070,994...69,086,992 		JBrowse link
G Ldhd lactate dehydrogenase D increases expression
multiple interactions		 ISO panobinostat results in increased expression of LDHD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr19:43,826,989...43,848,937
Ensembl chr19:43,826,993...43,848,937 		JBrowse link
G Lgals1 galectin 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA CTD PMID:27188386 NCBI chr 7:120,153,184...120,156,290
Ensembl chr 7:120,153,184...120,156,289 		JBrowse link
G Lgals3 galectin 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LGALS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:24,153,602...24,165,537
Ensembl chr15:24,141,651...24,165,537 		JBrowse link
G Lhfpl6 LHFPL tetraspan subfamily member 6 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:142,262,236...142,461,980
Ensembl chr 2:142,262,236...142,461,980 		JBrowse link
G Lhx2 LIM homeobox 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA
panobinostat results in decreased expression of LHX2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:22,628,674...22,658,447
Ensembl chr 3:22,640,545...22,658,446 		JBrowse link
G Lhx8 LIM homeobox 8 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA
panobinostat results in increased expression of LHX8 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:260,572,205...260,598,744
Ensembl chr 2:260,574,190...260,596,777 		JBrowse link
G Lifr LIF receptor subunit alpha multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA
panobinostat results in increased expression of LIFR mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415 		JBrowse link
G Lim2 lens intrinsic membrane protein 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA CTD PMID:27188386 NCBI chr 1:98,495,082...98,501,248
Ensembl chr 1:98,495,082...98,501,249 		JBrowse link
G Limch1 LIM and calponin homology domains 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of LIMCH1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:42,760,363...43,072,976
Ensembl chr14:42,762,587...43,072,843 		JBrowse link
G Lin28b lin-28 homolog B multiple interactions
decreases expression
affects expression		 ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LIN28B mRNA]; (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of LIN28B protein]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LIN28B mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of LIN28B protein]
panobinostat results in decreased expression of LIN28B protein
panobinostat affects the expression of LIN28B mRNA		 CTD PMID:26733615 NCBI chr20:50,482,536...50,580,273
Ensembl chr20:50,486,809...50,564,987 		JBrowse link
G Lingo2 leucine rich repeat and Ig domain containing 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LINGO2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:51,466,367...51,638,161 JBrowse link
G Lix1 limb and CNS expressed 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of LIX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:59,156,021...59,212,878
Ensembl chr 1:59,156,251...59,214,452 		JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr18:61,683,377...61,707,344
Ensembl chr18:61,685,117...61,707,317 		JBrowse link
G Lmf1 lipase maturation factor 1 increases expression ISO panobinostat results in increased expression of LMF1 mRNA CTD PMID:26272509 NCBI chr10:14,945,185...15,031,855
Ensembl chr10:14,945,265...15,031,942 		JBrowse link
G Lmo2 LIM domain only 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA
panobinostat results in decreased expression of LMO2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:93,909,156...93,931,888
Ensembl chr 3:93,909,156...93,931,871 		JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of LMO3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:172,942,023...173,005,630
Ensembl chr 4:172,942,020...173,005,634 		JBrowse link
G Lmo7 LIM domain 7 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA CTD PMID:27188386 NCBI chr15:86,242,911...86,458,512
Ensembl chr15:86,243,148...86,457,739 		JBrowse link
G Lnx1 ligand of numb-protein X 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA
panobinostat results in increased expression of LNX1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:36,047,136...36,149,740
Ensembl chr14:36,047,144...36,149,740 		JBrowse link
G LOC100302372 hypothetical protein LOC100302372 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA
panobinostat results in increased expression of KIAA0040 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr13:77,784,516...77,822,333
Ensembl chr13:77,784,808...77,822,333 		JBrowse link
G LOC100361016 oocyte specific homeobox 5-like increases expression
multiple interactions		 ISO Panobinostat results in increased expression of VENTX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr  X:93,064,417...93,067,181
Ensembl chr  X:93,064,686...93,065,675 		JBrowse link
G LOC100912195 protein BEX1-like multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA
panobinostat results in increased expression of BEX5 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:116,565,779...116,567,283
Ensembl chr 1:116,565,790...116,567,189 		JBrowse link
G LOC102551394 RING finger protein 175-like multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF175 mRNA
panobinostat results in decreased expression of RNF175 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:182,806,670...182,829,114 JBrowse link
G LOC102555635 zinc finger protein 39-like decreases expression
multiple interactions		 ISO Panobinostat results in decreased expression of ZNF785 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF785 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:45,193,771...45,211,045
Ensembl chr10:45,193,989...45,211,044 		JBrowse link
G LOC103690068 immortalization up-regulated protein-like multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA
panobinostat results in increased expression of C19ORF33 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:87,190,704...87,192,296
Ensembl chr 1:88,192,370...88,193,346
Ensembl chr 1:88,192,370...88,193,346 		JBrowse link
G LOC498368 similar to RIKEN cDNA 0610040J01 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C4ORF19 mRNA CTD PMID:27188386 NCBI chr14:46,050,752...46,134,770
Ensembl chr14:46,050,750...46,054,022 		JBrowse link
G LOC685680 similar to TPA-induced transmembrane protein increases expression
multiple interactions		 ISO panobinostat results in increased expression of C3ORF52 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr11:60,138,729...60,165,460
Ensembl chr11:60,140,130...60,164,655 		JBrowse link
G LOC688459 hypothetical protein LOC688459 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of C6ORF141 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 9:23,420,654...23,424,832
Ensembl chr 9:23,420,654...23,424,832 		JBrowse link
G LOC689959 hypothetical protein LOC689959 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA CTD PMID:27188386 NCBI chr 8:55,164,736...55,174,613
Ensembl chr 8:55,164,736...55,171,718 		JBrowse link
G LOC691113 hypothetical protein LOC691113 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:100,208,612...100,215,824
Ensembl chr 4:100,209,951...100,212,122 		JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LPAR6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:55,126,953...55,128,762
Ensembl chr15:55,126,953...55,128,761 		JBrowse link
G Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of LRIG1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:126,615,998...126,717,434
Ensembl chr 4:126,617,244...126,644,895 		JBrowse link
G Lrp12 LDL receptor related protein 12 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of LRP12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 7:78,859,784...78,930,850
Ensembl chr 7:78,859,784...78,930,832 		JBrowse link
G Lrp2 LDL receptor related protein 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA
panobinostat results in decreased expression of LRP2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:55,665,153...55,822,484
Ensembl chr 3:55,665,145...55,822,551 		JBrowse link
G Lrp8 LDL receptor related protein 8 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA CTD PMID:27188386 NCBI chr 5:127,404,348...127,476,636
Ensembl chr 5:127,404,450...127,476,641 		JBrowse link
G Lrrc17 leucine rich repeat containing 17 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA
panobinostat results in increased expression of LRRC17 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:10,108,184...10,138,652
Ensembl chr 4:10,108,192...10,138,652 		JBrowse link
G Lrrc3b leucine rich repeat containing 3B multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA
panobinostat results in decreased expression of LRRC3B mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr15:11,221,161...11,299,563
Ensembl chr15:11,298,478...11,299,257 		JBrowse link
G Lrrc55 leucine rich repeat containing 55 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of LRRC55 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:72,589,840...72,605,089
Ensembl chr 3:72,589,842...72,602,548 		JBrowse link
G Lrrc8b leucine rich repeat containing 8 VRAC subunit B multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA
panobinostat results in decreased expression of LRRC8B mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr14:5,414,872...5,482,004
Ensembl chr14:5,418,741...5,428,757 		JBrowse link
G Lrrc8e leucine rich repeat containing 8 VRAC subunit E multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA
panobinostat results in increased expression of LRRC8E mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr12:2,557,267...2,568,416
Ensembl chr12:2,557,275...2,568,382 		JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA CTD PMID:27188386 NCBI chr 9:98,139,484...98,268,148
Ensembl chr 9:98,190,829...98,257,735 		JBrowse link
G Lrrn3 leucine rich repeat neuronal 3 multiple interactions
increases expression
affects expression		 ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRN3 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRN3 mRNA]
panobinostat results in increased expression of LRRN3 mRNA
panobinostat affects the expression of LRRN3 mRNA		 CTD PMID:26272509, PMID:26733615, PMID:27188386 NCBI chr 6:61,374,328...61,405,195
Ensembl chr 6:61,374,328...61,405,195 		JBrowse link
G Lrrn4 leucine rich repeat neuronal 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA CTD PMID:27188386 NCBI chr 3:125,521,879...125,547,685
Ensembl chr 3:125,523,781...125,533,600 		JBrowse link
G LRRTM1 leucine rich repeat transmembrane neuronal 1 multiple interactions
affects expression		 ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRTM1 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRTM1 mRNA]
panobinostat affects the expression of LRRTM1 mRNA		 CTD PMID:26733615, PMID:27188386 NCBI chr 4:108,300,927...108,316,373
Ensembl chr 4:108,301,129...108,316,373 		JBrowse link
G Ly75 lymphocyte antigen 75 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LY75 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:46,369,749...46,457,182
Ensembl chr 3:46,365,165...46,457,201 		JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase increases expression
multiple interactions		 ISO panobinostat results in increased expression of LYN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 5:16,526,058...16,642,648
Ensembl chr 5:16,526,058...16,642,648 		JBrowse link
G Lypd3 Ly6/Plaur domain containing 3 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LYPD3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 1:81,499,856...81,504,306
Ensembl chr 1:81,499,821...81,504,318 		JBrowse link
G Lysmd2 LysM domain containing 2 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LYSMD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 8:82,560,363...82,576,662
Ensembl chr 8:82,560,761...82,577,019 		JBrowse link
G Lyzl6 lysozyme-like 6 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA
panobinostat results in increased expression of LYZL6 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr10:91,694,547...91,701,428
Ensembl chr10:91,694,547...91,699,424 		JBrowse link
G Lzts1 leucine zipper tumor suppressor 1 increases expression
multiple interactions		 ISO panobinostat results in increased expression of LZTS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr16:22,250,452...22,306,667
Ensembl chr16:22,250,470...22,306,662 		JBrowse link
G Mab21l2 mab-21 like 2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 2:185,849,749...185,852,833
Ensembl chr 2:185,850,232...185,852,759 		JBrowse link
G Macc1 MET transcriptional regulator MACC1 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA
panobinostat results in increased expression of MACC1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 6:147,315,232...147,392,530
Ensembl chr 6:147,315,328...147,394,269 		JBrowse link
G Macrod2 mono-ADP ribosylhydrolase 2 decreases expression
multiple interactions		 ISO panobinostat results in decreased expression of MACROD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 3:135,729,839...136,422,082 JBrowse link
G Macroh2a1 macroH2A.1 histone multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
Panobinostat results in decreased expression of MACROH2A1 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:9,282,109...9,344,698
Ensembl chr17:9,282,675...9,344,678 		JBrowse link
G Mafb MAF bZIP transcription factor B increases expression ISO panobinostat results in increased expression of MAFB mRNA CTD PMID:26272509 NCBI chr 3:156,338,993...156,340,913
Ensembl chr 3:156,339,004...156,340,913 		JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 multiple interactions
increases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA
panobinostat results in increased expression of MAGI2 mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr 4:10,995,241...12,472,423
Ensembl chr 4:10,995,234...11,610,518 		JBrowse link
G Mak male germ cell-associated kinase multiple interactions
decreases expression		 ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA
panobinostat results in decreased expression of MAK mRNA		 CTD PMID:26272509, PMID:27188386 NCBI chr17:21,531,651...21,567,742
Ensembl chr17:21,521,505...21,568,440 		JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 increases expression
multiple interactions